{
    "data": [
        {
            "title": "Is Norwegian Cruise Line (NCLH) Pricing In The Recovery After Recent Debt Refinancing Moves?",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>If you are wondering whether Norwegian Cruise Line Holdings is offering good value at around US$25.02, or if the recent buzz has already been priced in, this article is designed to help you frame that question clearly.</li> <li>The stock has seen returns of 5.4% over the last 7 days, 19.9% over the last 30 days, 9.8% year to date, 5.5% over 1 year and 60.9% over 3 years, while the 5 year return stands at a 24.0% decline.</li> <li>Recent attention around Norwegian Cruise Line Holdings has focused on how investors weigh the cruise sector's recovery story against balance sheet and demand related questions. This backdrop helps explain why the share price has been moving, while the medium and longer term picture remains in focus for many investors.</li> <li>On our valuation checks, Norwegian Cruise Line Holdings scores <a class=\"company-report-links\" href=\"https://www.simplywall.st/stocks/us/consumer-services/nyse-nclh/norwegian-cruise-line-holdings/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">5 out of 6</a> for being assessed as undervalued. Next, we will walk through what that means across different valuation methods and hint at a more detailed way to think about value that we will return to at the end.</li> </ul> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_industry_performance_contextual\" href=\"https://www.simplywall.st/stocks/us/consumer-services/nyse-nclh/norwegian-cruise-line-holdings/past\" rel=\"noopener noreferrer\" target=\"_blank\">Norwegian Cruise Line Holdings delivered 5.5% returns over the last year. See how this stacks up to the rest of the Hospitality industry.</a></p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h3>Approach 1: Norwegian Cruise Line Holdings Discounted Cash Flow (DCF) Analysis</h3> <p>A Discounted Cash Flow, or DCF, model takes a series of future cash flow projections and discounts them back to today, to estimate what the entire business might be worth in present value terms.</p> <p>For Norwegian Cruise Line Holdings, the model used is a 2 Stage Free Cash Flow to Equity approach. On a last twelve months basis, the company reported free cash flow of a $448.9 million loss, so the valuation leans heavily on future projections rather than recent cash generation.</p> <p>The projections indicate free cash flow turning positive and reaching $1,233 million in 2028, with further annual figures out to 2035 derived from analyst inputs and extrapolations by Simply Wall St. These ten-year free cash flow estimates, all in dollars, are then discounted back using the DCF framework.</p> <p>According to this model, the estimated intrinsic value is about $61.83 per share, compared with the current share price of around $25.02. This difference suggests a 59.5% discount to the DCF estimate, indicating that the shares are trading materially below this model‚Äôs assessment of value.</p> <p><strong>Result: UNDERVALUED</strong></p> <p>Our Discounted Cash Flow (DCF) analysis suggests Norwegian Cruise Line Holdings is undervalued by 59.5%. Track this in your <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_undervalued\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_undervalued\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a>, or discover <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">54 more high quality undervalued stocks</a>.</p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/consumer-services/nyse-nclh/norwegian-cruise-line-holdings/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NCLH Discounted Cash Flow as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/654e2d37-dd13-432b-8818-b17595112856/chart/dcf?date=2026-02-27\" width=\"746\"/></a><figcaption>NCLH Discounted Cash Flow as at Feb 2026</figcaption></figure> <p><a class=\"company-report-links\" data-vars-link-type=\"dcf_explainer_cta\" href=\"https://www.simplywall.st/stocks/us/consumer-services/nyse-nclh/norwegian-cruise-line-holdings/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Norwegian Cruise Line Holdings.</a></p> <h3>Approach 2: Norwegian Cruise Line Holdings Price vs Earnings</h3> <p>For profitable companies, the P/E ratio is a common way to gauge how much investors are paying for each dollar of earnings. This makes it a useful cross check against the DCF result you just saw.</p> <p>What counts as a \"normal\" P/E is usually shaped by how fast earnings are expected to grow and how risky those earnings are. Higher growth and perceived resilience can justify a higher multiple, while more risk or slower growth often points to a lower one.</p> <p>Norwegian Cruise Line Holdings currently trades on a P/E of 17.17x. That sits below the Hospitality industry average of about 23.54x and the peer group average of 43.21x. Simply Wall St also calculates a proprietary ‚ÄúFair Ratio‚Äù of 35.89x, which reflects factors such as earnings growth, profit margins, industry, market cap and company specific risks.</p> <p>This Fair Ratio is designed to be more tailored than a simple comparison with peers or the broad industry. It adjusts for company specific characteristics rather than assuming all firms deserve the same multiple. Set against this Fair Ratio of 35.89x, the current P/E of 17.17x suggests the shares are trading at a discount on this metric.</p> <p><strong>Result: UNDERVALUED</strong></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/consumer-services/nyse-nclh/norwegian-cruise-line-holdings/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NYSE:NCLH P/E Ratio as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/654e2d37-dd13-432b-8818-b17595112856/chart/pe-multiple-vs-industry?date=2026-02-27\" width=\"746\"/></a><figcaption>NYSE:NCLH P/E Ratio as at Feb 2026</figcaption></figure> <p>P/E ratios tell one story, but what if the real opportunity lies elsewhere? <a class=\"company-report-links\" data-vars-link-type=\"cta_preferred_multiple_contextual\" href=\"https://simplywall.st/discover/investing-ideas/473625/top-founder-led-companies/us\" rel=\"noopener noreferrer\" target=\"_blank\">Start investing in legacies, not executives. Discover our 19 top founder-led companies</a>.</p> <h3>Upgrade Your Decision Making: Choose your Norwegian Cruise Line Holdings Narrative</h3> <p>Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives, which are simple stories you create that link your view of Norwegian Cruise Line Holdings to concrete numbers like future revenue, earnings, margins and an assumed fair value, all hosted on Simply Wall St's Community page where millions of investors share their perspectives.</p> <p>A Narrative connects three pieces in one place: the company story you believe in, the financial forecast that story implies and the fair value that follows from those assumptions. It then compares that fair value with the current share price to help you decide whether you see room to buy more, trim or simply watch.</p> <p>Because Narratives on Simply Wall St update automatically when new earnings, news or valuation inputs are added, you can see in real time how different views stack up. For example, one Norwegian Cruise Line Holdings Narrative currently anchors on a fair value near US$19.00, while another sits closer to about US$45.00, showing how two investors using the same company can reach very different conclusions based on their assumptions and what risks or opportunities they choose to focus on.</p> <p>For Norwegian Cruise Line Holdings however, we will make it really easy for you with previews of two leading Norwegian Cruise Line Holdings Narratives:</p> <p>On Simply Wall St, Narratives give you a structured way to line up your view of the business with specific assumptions on growth, margins and a fair value, so you can see exactly what would need to be true for your thesis to hold.</p> <p><a href=\"/us/consumer-services/nyse-nclh/norwegian-cruise-line-holdings/s8dfnukw-norwegian-cruise-line-holdings-will-continue-to-rise-in-2025?utm_medium=finance_user&amp;utm_campaign=cta_bull_narrative_link&amp;utm_source=post\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong>üêÇ Norwegian Cruise Line Holdings Bull Case</strong></a></p> <p>Fair value in this bullish Narrative: US$45.00 per share</p> <p>Gap to this fair value: about 44% below the Narrative fair value at the recent price of US$25.02</p> <p>Assumed revenue growth in the Narrative: 26.04% per year</p> <ul> <li>Focuses on cruise travel demand, with AAA data pointing to record US cruise passengers in 2025 compared with both last year and pre COVID levels.</li> <li>Highlights recent refinancing of US$1.8b of senior notes and access to a US$1.7b revolving facility as key moves to reshape the balance sheet and extend debt maturities.</li> <li>Points to sector wide strength, technical momentum, a US$34 price target from one major bank and ongoing fleet investments as reasons the author sees meaningful upside potential.</li> </ul> <p><a href=\"/us/consumer-services/nyse-nclh/norwegian-cruise-line-holdings/eydrh5kh-tighter-environmental-rules-and-heavy-debt-will-squeeze-margins-x2g6?utm_medium=finance_user&amp;utm_campaign=cta_bear_narrative_link&amp;utm_source=post\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong>üêª Norwegian Cruise Line Holdings Bear Case</strong></a></p> <p>Fair value in this cautious Narrative: US$19.00 per share</p> <p>Gap to this fair value: about 32% above the Narrative fair value at the recent price of US$25.02</p> <p>Assumed revenue growth in the Narrative: 9.27% per year</p> <ul> <li>Flags tighter environmental regulation, overtourism concerns and potential restrictions at key ports as long term risks for costs, access to high value routes and demand.</li> <li>Emphasizes the company‚Äôs debt load and interest costs, as well as demographic shifts among younger travelers, as constraints on reinvestment and earnings power.</li> <li>Works through a bearish analyst framework that assumes 8.2% annual revenue growth, higher profit margins and a future P/E of 10.1x, leading to a US$23.00 bearish price target that sits close to the recent share price.</li> </ul> <p>Together, these Narratives frame a wide range of outcomes, from a bullish view anchored on strong cruise demand and refinancing progress to a more cautious stance centered on regulation, leverage and capacity risks. The value for you is in comparing their assumptions with your own and deciding which story, if either, lines up with how you see Norwegian Cruise Line Holdings today.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_generic_community_narrative\" href=\"https://simplywall.st/features/community-narratives\" rel=\"noopener noreferrer\" target=\"_blank\">Curious how numbers become stories that shape markets? Explore Community Narratives</a></p> <p>Do you think there's more to the story for Norwegian Cruise Line Holdings? <a class=\"company-report-links\" data-vars-link-type=\"cta_create_narrative_community\" href=\"https://simplywall.st/stock/NYSE/NCLH\" rel=\"noopener noreferrer\" target=\"_blank\">Head over to our Community to see what others are saying!</a></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/consumer-services/nyse-nclh/norwegian-cruise-line-holdings\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NYSE:NCLH 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/654e2d37-dd13-432b-8818-b17595112856/chart/quote-price?date=2026-02-27\" width=\"746\"/></a><figcaption>NYSE:NCLH 1-Year Stock Price Chart</figcaption></figure> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\">Valuation is complex, but we're here to simplify it.</h3><p>Discover if Norwegian Cruise Line Holdings might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"/stocks/us/consumer-services/nyse-nclh/norwegian-cruise-line-holdings/valuation\" target=\"_blank\">Access Free Analysis</a></div></div>",
            "pub_date": "2026-02-28 01:26:16",
            "link": "https://simplywall.st/stocks/us/consumer-services/nyse-nclh/norwegian-cruise-line-holdings/news/is-norwegian-cruise-line-nclh-pricing-in-the-recovery-after",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Assessing Inspire Medical Systems (INSP) Valuation After New CMS Billing Codes For Sleep Apnea Therapy",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><p>The Centers for Medicare &amp; Medicaid Services has approved new HCPCS billing codes for hypoglossal nerve stimulation procedures, including Inspire Medical Systems (INSP), effective January 2026, resolving prior reimbursement uncertainty for its obstructive sleep apnea therapy.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/us/healthcare/nyse-insp/inspire-medical-systems\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for Inspire Medical Systems.</a></p> <p>The new CMS codes arrive after a sharp swing in sentiment, with a 14.85% 1 day share price return lifting the stock to US$68.05, even though the 1 year total shareholder return of 63.02% and 3 year total shareholder return of 73.74% remain deeply negative. This suggests recent momentum is improving from a weak longer term backdrop.</p> <p>If this reimbursement news has you looking more broadly at healthcare technology, it could be a good moment to scan <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_healthcare_ai\" href=\"https://simplywall.st/discover/investing-ideas/434426/healthcare-ai/us\" rel=\"noopener noreferrer\" target=\"_blank\">29 healthcare AI stocks</a> for other potential ideas in the sector.</p> <p>With the stock at US$68.05, a value score of 5, an indicated 51.13% intrinsic discount, and trading roughly 14% below the current analyst price target, investors now have to ask: is this a fresh entry point, or is the market already pricing in future growth?</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Most Popular Narrative: 45.3% Undervalued</h2> <p>With Inspire Medical Systems last closing at $68.05 against a narrative fair value of $124.40, the gap between price and modeled worth is wide enough to grab attention.</p> <blockquote> <p><em>The recent delay in transitioning centers to the Inspire V next-generation system, including slower onboarding, delayed SleepSync implementation, and the Medicare billing update, are transitory issues. As these barriers resolve (with Medicare billing now live and most centers expected to complete onboarding by end of Q3), procedure volumes and revenue growth are positioned to reaccelerate in 2026 as pent-up demand is realized.</em></p> </blockquote> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_narrative_prompt_after_quote\" href=\"https://www.simplywall.st/narratives/7g7m5uxk-sector-dislocations-and-transitory-headwinds-will-create-long-term-upside-opportunity\" rel=\"noopener noreferrer\" target=\"_blank\">Read the complete narrative.</a></p> <p>Curious what kind of revenue path and profit margin shift could justify that gap, and what future earnings multiple sits behind it all? The full narrative lays out a detailed set of growth, margin and discount rate assumptions, plus how those translate into a long term valuation roadmap for Inspire Medical Systems.</p> <p><strong>Result: Fair Value of $124.40 (UNDERVALUED)</strong></p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_ai_narrative\" href=\"https://www.simplywall.st/narratives/7g7m5uxk-sector-dislocations-and-transitory-headwinds-will-create-long-term-upside-opportunity\" rel=\"noopener noreferrer\" target=\"_blank\">Have a read of the narrative in full and understand what's behind the forecasts.</a></p> <p>However, there are still real pressure points, including a slower Inspire V rollout and reimbursement or coding shifts that could weigh on volumes and keep costs elevated.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/us/healthcare/nyse-insp/inspire-medical-systems\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this Inspire Medical Systems narrative.</a></p> <h2>Next Steps</h2> <p>If this mix of optimism and concern feels familiar, now is a good time to look at the figures yourself and decide where you stand, starting with <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/us/healthcare/nyse-insp/inspire-medical-systems\" rel=\"noopener noreferrer\" target=\"_blank\">3 key rewards and 2 important warning signs</a>.</p> <h2>Looking for more investment ideas?</h2> <p>If you only focus on one stock, you can miss other opportunities, so use the Simply Wall Street Screener to quickly surface fresh ideas that fit your style.</p> <ul> <li>Target potential mispricings by scanning <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">54 high quality undervalued stocks</a> that our filters flag as trading below their estimated worth.</li> <li>Prioritize staying power by reviewing <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_solid_balance_sheet\" href=\"https://simplywall.st/discover/investing-ideas/10146/solid-balance-sheet-and-fundamentals/us\" rel=\"noopener noreferrer\" target=\"_blank\">solid balance sheet and fundamentals stocks screener (41 results)</a> that pair healthier finances with more resilient fundamentals.</li> <li>Spot under the radar opportunities by checking the <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undiscovered_gems\" href=\"https://simplywall.st/discover/investing-ideas/473622/high-quality-undiscovered-gems/us\" rel=\"noopener noreferrer\" target=\"_blank\">screener containing 24 high quality undiscovered gems</a> that have quality metrics but limited market attention so far.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><p>‚Ä¢ Dividend Powerhouses (3%+ Yield)<br/>‚Ä¢ Undervalued Small Caps with Insider Buying<br/>‚Ä¢ High growth Tech and AI Companies<br/><br/>Or build your own from over 50 metrics.</p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/stock-screener\" target=\"_blank\">Explore Now for Free</a></div></div>",
            "pub_date": "2026-02-28 01:26:16",
            "link": "https://simplywall.st/stocks/us/healthcare/nyse-insp/inspire-medical-systems/news/assessing-inspire-medical-systems-insp-valuation-after-new-c",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Assessing Healthcare Services Group (HCSG) Valuation After Strong Recent Share Price Momentum",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Context for Healthcare Services Group</h2> <p>With no single headline event driving attention today, Healthcare Services Group (HCSG) is on many investors‚Äô radar because of its recent share performance and current valuation signals in the commercial services space.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/us/commercial-services/nasdaq-hcsg/healthcare-services-group\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for Healthcare Services Group.</a></p> <p>At a share price of $21.76, Healthcare Services Group has seen firm momentum build recently, with a 30 day share price return of 16.74% and a 1 year total shareholder return of 106.26% contrasting with a 5 year total shareholder return decline of 15.42%. The current move is therefore strong relative to its longer term record.</p> <p>If this kind of rebound in a single name has your attention, it could be a good moment to broaden your search and check out <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_healthcare_ai\" href=\"https://simplywall.st/discover/investing-ideas/434426/healthcare-ai/us\" rel=\"noopener noreferrer\" target=\"_blank\">29 healthcare AI stocks</a> as another way to spot opportunities across the sector.</p> <p>With shares up sharply in the short term and trading below some estimates of intrinsic value, the central question is whether Healthcare Services Group remains undervalued or whether the market is already accounting for potential future growth.</p> <h2>Most Popular Narrative: 11.2% Undervalued</h2> <p>Healthcare Services Group‚Äôs most followed narrative puts fair value at $24.50 versus the current $21.76, framing the current share price as below that estimate and highlighting what assumptions would need to play out for the gap to close.</p> <blockquote> <p><em>Strong operational execution, including 90%+ client retention, increased cross-selling of dining services into environmental accounts, and a focus on bundled solutions, should drive recurring revenues and improve earnings consistency over time.</em></p> </blockquote> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_narrative_prompt_after_quote\" href=\"https://www.simplywall.st/narratives/ujhc0ire-stable-industry-trends-and-aging-demographics-will-drive-sector-opportunities\" rel=\"noopener noreferrer\" target=\"_blank\">Read the complete narrative.</a></p> <p>Want to see what sits behind that confidence in recurring revenue? The narrative leans heavily on steady growth, margin lift and a future earnings multiple that has to do some work. If you are curious which assumptions really carry the fair value, the full story joins the dots in detail.</p> <p><strong>Result: Fair Value of $24.50 (UNDERVALUED)</strong></p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_ai_narrative\" href=\"https://www.simplywall.st/narratives/ujhc0ire-stable-industry-trends-and-aging-demographics-will-drive-sector-opportunities\" rel=\"noopener noreferrer\" target=\"_blank\">Have a read of the narrative in full and understand what's behind the forecasts.</a></p> <p>However, the story can change quickly if large clients restructure again or if wage and staffing pressures squeeze margins more than contracts can pass through.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/us/commercial-services/nasdaq-hcsg/healthcare-services-group\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this Healthcare Services Group narrative.</a></p> <h2>Next Steps</h2> <p>If this mix of optimism and concern feels familiar, do not wait on others to decide the story for you. Instead, review the balance of <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/us/commercial-services/nasdaq-hcsg/healthcare-services-group\" rel=\"noopener noreferrer\" target=\"_blank\">3 key rewards and 1 important warning sign</a> and weigh it against your own view.</p> <h2>Looking for more investment ideas?</h2> <p>You have already done the work to understand Healthcare Services Group, so do not stop there when the same tools can help you spot other opportunities just as early.</p> <ul> <li>Scan for potential bargains by checking companies that feature in our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">54 high quality undervalued stocks</a>, where market prices sit below what the fundamentals might justify.</li> <li>Focus on cash returns by reviewing the <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_dividend\" href=\"https://simplywall.st/discover/investing-ideas/473528/dividend-fortresses/us\" rel=\"noopener noreferrer\" target=\"_blank\">15 dividend fortresses</a>, built for investors who want higher yielding companies that still keep an eye on resilience.</li> <li>Limit downside risk by starting with the <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_low_risk\" href=\"https://simplywall.st/discover/investing-ideas/473631/low-risk-leaders/us\" rel=\"noopener noreferrer\" target=\"_blank\">80 resilient stocks with low risk scores</a>, a list that highlights businesses scoring well on financial strength and overall risk checks.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\">Valuation is complex, but we're here to simplify it.</h3><p>Discover if Healthcare Services Group might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"/stocks/us/commercial-services/nasdaq-hcsg/healthcare-services-group/valuation\" target=\"_blank\">Access Free Analysis</a></div></div>",
            "pub_date": "2026-02-28 01:26:15",
            "link": "https://simplywall.st/stocks/us/commercial-services/nasdaq-hcsg/healthcare-services-group/news/assessing-healthcare-services-group-hcsg-valuation-after-str",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Assessing Lloyds Banking Group (LSE:LLOY) Valuation As Recent Momentum Cools",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><p>Lloyds Banking Group (LSE:LLOY) is back in focus for investors after recent share price moves, with the stock showing different return patterns over the past week, month and past 3 months.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/gb/banks/lse-lloy/lloyds-banking-group-shares\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for Lloyds Banking Group.</a></p> <p>At a share price of ¬£1.049, Lloyds Banking Group has seen short term share price momentum cool compared to its recent 90 day share price return of 9.11%. At the same time, the 1 year total shareholder return of 53.60% and 3 year total shareholder return of almost 1.4x highlight how much overall investor sentiment has shifted over time.</p> <p>If this move in a major UK bank has you thinking about where else capital is flowing, it could be a good moment to scan <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_founder_led\" href=\"https://simplywall.st/discover/investing-ideas/473625/top-founder-led-companies/gb\" rel=\"noopener noreferrer\" target=\"_blank\">4 top founder-led companies</a> for fresh ideas beyond the large caps.</p> <p>Lloyds now trades at ¬£1.049 with an indicated intrinsic discount of around 42%, and a small gap to analyst targets. This raises a key question for you: is there genuine value left here, or is future growth already priced in?</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Most Popular Narrative: 5.2% Undervalued</h2> <p>The most followed narrative currently points to a fair value of ¬£1.11 for Lloyds Banking Group, slightly above the ¬£1.049 last close, with that view built on detailed revenue, margin and discount rate assumptions.</p> <blockquote> <p><em>Lloyds' significant progress in digital transformation, including expanding mobile first services for 21 million users, rolling out a new digital remortgage journey, and leveraging AI innovation, continues to drive operating cost reductions and enhances efficiency, positioning the company to support sustained long term margin expansion and higher earnings.</em></p> </blockquote> <p><em><a class=\"company-report-links\" data-vars-link-type=\"cta_narrative_prompt_after_quote\" href=\"https://www.simplywall.st/narratives/z1hgb05r-analysts-note-modest-gains-for-lloyds-as-valuation-and-dividend-increase-amid-positive-updates\" rel=\"noopener noreferrer\" target=\"_blank\">Read the complete narrative.</a></em></p> <p>Curious what sits behind that fair value gap? The narrative leans on steady revenue expansion, firmer profit margins and a specific future earnings multiple baked into the model. Want to see how those pieces fit together and what the discount rate is doing in the valuation?</p> <p><strong>Result: Fair Value of ¬£1.11 (UNDERVALUED)</strong></p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_ai_narrative\" href=\"https://www.simplywall.st/narratives/z1hgb05r-analysts-note-modest-gains-for-lloyds-as-valuation-and-dividend-increase-amid-positive-updates\" rel=\"noopener noreferrer\" target=\"_blank\">Have a read of the narrative in full and understand what's behind the forecasts.</a></p> <p>However, this depends on the UK economy holding up and on Lloyds staying ahead of fintech rivals that could pressure margins and customer loyalty.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/gb/banks/lse-lloy/lloyds-banking-group-shares\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this Lloyds Banking Group narrative.</a></p> <h2>Another Angle on Valuation</h2> <p>While the fair value narrative points to Lloyds being undervalued, the current P/E ratio of 14.7x paints a very different picture. It sits above both the European banks average of 11.1x and the peer average of 11.6x, and above a fair ratio of 10.5x. This lifts the valuation risk if sentiment cools.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"alternate_preferred_multiple_cta\" href=\"https://www.simplywall.st/stocks/gb/banks/lse-lloy/lloyds-banking-group-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">See what the numbers say about this price ‚Äî find out in our valuation breakdown.</a></p> <p></p><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/gb/banks/lse-lloy/lloyds-banking-group-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"LSE:LLOY P/E Ratio as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/6cb8c01c-2f51-4500-a9d6-e886a74c0392/chart/pe-multiple-vs-industry?date=2026-02-27\" width=\"746\"/></a><figcaption>LSE:LLOY P/E Ratio as at Feb 2026</figcaption></figure><p> </p><h2>Next Steps</h2> <p>Mixed signals so far, or does the story feel clear to you already? If you want to act while sentiment is split, weigh up <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/gb/banks/lse-lloy/lloyds-banking-group-shares\" rel=\"noopener noreferrer\" target=\"_blank\">3 key rewards and 2 important warning signs</a> and decide where you stand.</p> <h2>Looking for more investment ideas?</h2> <p>If you are serious about staying one step ahead, do not stop at one bank. Use the screener to spot fresh angles before everyone else piles in.</p> <ul> <li>Target reliability by scanning our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_low_risk\" href=\"https://simplywall.st/discover/investing-ideas/473631/low-risk-leaders/gb\" rel=\"noopener noreferrer\" target=\"_blank\">5 resilient stocks with low risk scores</a> that focus on businesses with more resilient risk profiles and potentially steadier performance through different market conditions.</li> <li>Hunt for pricing gaps with the <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/gb\" rel=\"noopener noreferrer\" target=\"_blank\">5 high quality undervalued stocks</a>, where you can filter for companies that trade below certain valuation metrics while still showing solid fundamentals.</li> <li>Strengthen your income ideas by checking the <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_dividend\" href=\"https://simplywall.st/discover/investing-ideas/473528/dividend-fortresses/gb\" rel=\"noopener noreferrer\" target=\"_blank\">4 dividend fortresses</a>, built to surface higher yield payers that match specific stability and payout criteria you care about.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><p>‚Ä¢ Dividend Powerhouses (3%+ Yield)<br/>‚Ä¢ Undervalued Small Caps with Insider Buying<br/>‚Ä¢ High growth Tech and AI Companies<br/><br/>Or build your own from over 50 metrics.</p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/stock-screener\" target=\"_blank\">Explore Now for Free</a></div></div>",
            "pub_date": "2026-02-28 01:26:15",
            "link": "https://simplywall.st/stocks/gb/banks/lse-lloy/lloyds-banking-group-shares/news/assessing-lloyds-banking-group-lselloy-valuation-as-recent-m",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Principal Financial Group Adds Flexible Shelf Capacity For Future Funding Choices",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>Principal Financial Group (NasdaqGS:PFG) has filed a comprehensive shelf registration statement.</li> <li>The filing covers multiple types of securities, including equity and debt instruments.</li> <li>The shelf registration allows the company to raise capital in the future in amounts and at times it selects.</li> </ul> <p>Principal Financial Group, a diversified financial services company focused on retirement, asset management, and insurance solutions, now has an additional tool it can use when it chooses to access capital markets. For investors, a shelf registration like this often sits in the background until management decides conditions are suitable to issue securities. It does not commit the company to raise funds, but it sets up the framework to do so efficiently.</p> <p>This filing indicates that management is seeking flexibility to respond if funding needs, acquisition opportunities, or regulatory capital requirements arise. The key thing to monitor is how, when, and in what form NasdaqGS:PFG eventually uses this capacity, because equity, debt, or hybrid offerings can affect the risk profile and potential returns in different ways.</p> <p>Stay updated on the most important news stories for <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://www.simplywall.st/stocks/us/insurance/nasdaq-pfg/principal-financial-group/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Principal Financial Group</a> by adding it to your <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a>. Alternatively, explore our <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/stock/NasdaqGS/PFG\" rel=\"noopener noreferrer\" target=\"_blank\">Community</a> to discover new perspectives on Principal Financial Group.</p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st/stocks/us/insurance/nasdaq-pfg/principal-financial-group/future\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NasdaqGS:PFG Earnings &amp; Revenue Growth as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/28c3aefb-566f-4566-93f9-98eb48d58ce8/chart/earnings-and-revenue-growth?date=2026-02-27\" width=\"746\"/></a><figcaption>NasdaqGS:PFG Earnings &amp; Revenue Growth as at Feb 2026</figcaption></figure> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_news_risk_alert\" href=\"https://www.simplywall.st/stocks/us/insurance/nasdaq-pfg/principal-financial-group\" rel=\"noopener noreferrer\" target=\"_blank\">We've flagged 0 risks for Principal Financial Group. See which could impact your investment.</a></p> <p>This universal shelf gives Principal Financial Group a ready made menu of funding options, from common and preferred equity to debt, warrants, and bundled purchase units. For a diversified insurer and asset manager, that kind of flexibility can matter when you think about regulatory capital, potential acquisitions, or refinancing existing obligations. The filing itself does not change earnings or cash flows today, but it can influence how management funds future growth or supports shareholder returns such as dividends and buybacks.</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h3>How This Fits Into The Principal Financial Group Narrative</h3> <ul> <li>The ability to issue a mix of securities could support the existing focus on retirement and global asset management if management chooses to fund organic growth, technology, or bolt on deals that build scale in those areas.</li> <li>If equity or equity linked securities are issued, that could run against the narrative of capital strength and cash returns by introducing dilution, especially when analysts already hold mostly neutral views.</li> <li>The shelf increases optionality around future M&amp;A or balance sheet moves, which is not fully captured in the existing discussion that focuses more on margins, flows, and pricing rather than funding structure.</li> </ul> <p>Knowing what a company is worth starts with understanding its story.\n                        <a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/narratives/6q99incu-analyst-commentary-drives-modest-price-target-increases-for-principal-financial-group-amid-stable-outlook\" rel=\"noopener noreferrer\" target=\"_blank\">Check out one of the top narratives in the Simply Wall St Community for Principal Financial Group</a> to help decide what it's worth to you.</p> <h3>The Risks and Rewards Investors Should Consider</h3> <ul> <li>‚ö†Ô∏è Potential issuance of common stock or equity linked securities could dilute existing holders if used heavily for funding or acquisitions.</li> <li>‚ö†Ô∏è If new debt securities are issued on less favorable terms, interest costs could pressure margins in a sector where peers like MetLife and Prudential also compete for capital.</li> <li>üéÅ A pre cleared shelf can let Principal move quickly if attractive acquisition or partnership opportunities appear in retirement or asset management, without long lead times.</li> <li>üéÅ Flexible capital tools give management more ways to balance growth investments, dividends, and buybacks, which may appeal to income focused investors if used conservatively.</li> </ul> <h3>What To Watch Going Forward</h3> <p>From here, keep an eye on whether Principal starts to issue any securities off this shelf, in what size, and for what stated purpose. The mix between equity and debt will matter for earnings per share, leverage and dividend capacity, especially given recent analyst caution on upside potential. Any use of proceeds for deals, technology, or product expansion in retirement and asset management will also help you judge if new capital is supporting the existing business plan or stretching beyond it.</p> <p>To stay informed on how the latest news affects the investment narrative for Principal Financial Group, visit the\n                        <a class=\"company-report-links\" href=\"https://www.simplywall.st/stock/NasdaqGS/PFG\" rel=\"noopener noreferrer\" target=\"_blank\">community page for Principal Financial Group</a> so you do not miss updates on the top community narratives.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-02-28 01:21:20",
            "link": "https://simplywall.st/stocks/us/insurance/nasdaq-pfg/principal-financial-group/news/principal-financial-group-adds-flexible-shelf-capacity-for-f",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Invitation Homes Weighs Rate Cut Hopes Against Rising Costs And Rules",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>Invitation Homes (NYSE:INVH) is in focus as investors weigh the potential impact of expected Federal Reserve rate cuts on its borrowing costs and expansion plans.</li> <li>The company is also contending with higher operating expenses, including insurance and property taxes, which are affecting the economics of its single family rental portfolio.</li> <li>Regulatory scrutiny of corporate ownership of single family homes and tenant protections continues to build, adding another layer of risk for the business.</li> </ul> <p>For you as an investor, the story around NYSE:INVH sits at the intersection of interest rate expectations, housing policy, and real estate costs. The stock trades at $26.3, with a 7.2% gain over the past five years but a 1 year return of an 18% decline and a 3 year return of a 4.7% decline, which points to a bumpier recent stretch. Those mixed results help explain why new developments on rates, regulation, and expenses matter so much at the moment.</p> <p>The key questions center on how much relief potential Fed rate cuts might provide against rising insurance, tax, and compliance costs, and how regulators ultimately shape the rules for large owners of single family rentals. The balance between these forces could influence how Invitation Homes manages growth, maintains occupancy, and supports its ability to deliver consistent returns over time.</p> <p>Stay updated on the most important news stories for <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://www.simplywall.st/stocks/us/real-estate/nyse-invh/invitation-homes/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Invitation Homes</a> by adding it to your <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a>. Alternatively, explore our <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/stock/NYSE/INVH\" rel=\"noopener noreferrer\" target=\"_blank\">Community</a> to discover new perspectives on Invitation Homes.</p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/real-estate/nyse-invh/invitation-homes\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NYSE:INVH 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/a9cd8cdc-3090-43bd-b2b6-15dd8ef0e4f2/chart/quote-price?date=2026-02-27\" width=\"746\"/></a><figcaption>NYSE:INVH 1-Year Stock Price Chart</figcaption></figure> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_news_ownership\" href=\"https://www.simplywall.st/stocks/us/real-estate/nyse-invh/invitation-homes/ownership\" rel=\"noopener noreferrer\" target=\"_blank\">See which insiders are buying and buying and selling Invitation Homes following this latest news.</a></p> <p>For Invitation Homes, the latest earnings and guidance land in the middle of the current debate around rate-cut speculation, rising costs, and tighter rules for large landlords. Same-store core revenue growth guidance of 1.3% to 2.5% for 2026 indicates that management is not assuming aggressive rent growth, even though 2025 revenue, net income, and earnings per share were higher than the prior year. The completed US$100.05m buyback, covering 0.59% of shares, also adds context for recent investor activity by indicating that the company has been returning capital while investors trade the stock on interest-rate expectations.</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h3>How This Fits Into The Invitation Homes Narrative</h3> <ul> <li>Measured 2026 same-store revenue growth guidance and recent earnings support the narrative that steady rental demand and operational efficiency can underpin long-term earnings for a large single-family rental owner.</li> <li>Soft pricing on new leases and rising operating expenses challenge the idea that Sun Belt and suburban markets automatically translate into strong rent growth and expanding margins.</li> <li>The scale of recent share repurchases and the impact of regulatory scrutiny on future acquisition-driven growth are not fully captured in the narrative and could influence how investors think about portfolio expansion versus capital returns.</li> </ul> <p>Knowing what a company is worth starts with understanding its story.\n<a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/narratives/4lj7ec1o-analysts-adjust-invitation-homes-price-targets-amid-sector-reassessment-and-modest-valuation-changes\" rel=\"noopener noreferrer\" target=\"_blank\"> Check out one of the top narratives in the Simply Wall St Community for Invitation Homes</a> to help decide what it is worth to you.</p> <h3>The Risks and Rewards Investors Should Consider</h3> <ul> <li>‚ö†Ô∏è Analysts highlight that earnings are forecast to decline by an average of 2% per year over the next 3 years, which could limit support for a high P/E if growth expectations reset.</li> <li>‚ö†Ô∏è Interest payments are not well covered by earnings, which can matter more for a rate-sensitive REIT if borrowing costs do not ease as quickly as some investors expect.</li> <li>üéÅ Earnings grew by 29.5% over the past year, giving investors a recent track record of profit growth to weigh against more cautious forward expectations.</li> <li>üéÅ The stock is described as trading at 41.9% below one estimate of fair value, which some investors may see as room for upside if the single-family rental model remains resilient versus peers such as American Homes 4 Rent and Tricon Residential.</li> </ul> <h3>What To Watch Going Forward</h3> <p>From here, you may want to watch how Invitation Homes converts its 1.3% to 2.5% same-store core revenue growth target into cash flow after higher insurance, taxes, and maintenance, as well as how renewal rent trends compare with weaker new-lease pricing. Fed policy decisions and any change in commentary around institutional ownership of single-family homes could influence both borrowing costs and sentiment. It is also worth tracking how management balances further buybacks against potential portfolio growth, especially relative to other residential REITs such as Equity Residential and Mid-America Apartment Communities.</p> <p>To stay updated on how the latest news impacts the investment narrative for Invitation Homes, visit the\n<a class=\"company-report-links\" href=\"https://www.simplywall.st/stock/NYSE/INVH\" rel=\"noopener noreferrer\" target=\"_blank\"> community page for Invitation Homes</a> to follow the top community narratives.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><p>‚Ä¢ Dividend Powerhouses (3%+ Yield)<br/>‚Ä¢ Undervalued Small Caps with Insider Buying<br/>‚Ä¢ High growth Tech and AI Companies<br/><br/>Or build your own from over 50 metrics.</p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/stock-screener\" target=\"_blank\">Explore Now for Free</a></div></div>",
            "pub_date": "2026-02-28 01:21:20",
            "link": "https://simplywall.st/stocks/us/real-estate/nyse-invh/invitation-homes/news/invitation-homes-weighs-rate-cut-hopes-against-rising-costs",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Is CorMedix (CRMD) Pricing Reflect Recent Share Weakness Or Future Growth Potential",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>If you are wondering whether CorMedix stock is priced attractively or already baking in a lot of optimism, you are in the right place to unpack what the current share price might be implying.</li> <li>CorMedix recently closed at US$7.35, with returns of 3.8% over the past 7 days, a 5.2% decline over 30 days, a 39.6% decline year to date, and a 28.3% decline over 1 year, set against a 73.8% return over 3 years and 3.7% over 5 years.</li> <li>Recent coverage of CorMedix has focused on its position within the pharmaceuticals and biotech space and how investors are reacting to company specific developments rather than broad market moves. This backdrop helps explain why the share price has seen both shorter term weakness and stronger multi year returns as sentiment has shifted over time.</li> <li>On our valuation checks, CorMedix scores a <a class=\"company-report-links\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crmd/cormedix/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">6 out of 6</a>. This signals that every one of the six tests currently points to undervaluation. In the sections ahead we will walk through those methods, then finish with a more rounded way to think about what the valuation really means for you.</li> </ul> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_industry_underperformer\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crmd/cormedix/future\" rel=\"noopener noreferrer\" target=\"_blank\">Find out why CorMedix's -28.3% return over the last year is lagging behind its peers.</a></p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h3>Approach 1: CorMedix Discounted Cash Flow (DCF) Analysis</h3> <p>A Discounted Cash Flow, or DCF, model takes estimates of the cash a company might generate in the future and discounts those back to today, aiming to arrive at an intrinsic value per share based on those projected cash flows.</p> <p>For CorMedix, the model used is a 2 Stage Free Cash Flow to Equity approach, working with recent Free Cash Flow of about $73.9 million. Analysts provide specific Free Cash Flow estimates for the coming years, and Simply Wall St then extrapolates further to build a 10 year path. On this basis, projected Free Cash Flow reaches $209.8 million in 2030, with additional years beyond that also modeled in millions of US dollars.</p> <p>When all those future cash flows are discounted back to today, the DCF model produces an estimated intrinsic value of about $91.95 per share. Compared to the recent share price of US$7.35, this suggests the stock is 92.0% undervalued according to this method.</p> <p><strong>Result: UNDERVALUED</strong></p> <p>Our Discounted Cash Flow (DCF) analysis suggests CorMedix is undervalued by 92.0%. Track this in your <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_undervalued\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_undervalued\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a>, or discover <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">54 more high quality undervalued stocks</a>.</p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/pharmaceuticals-biotech/nasdaq-crmd/cormedix/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"CRMD Discounted Cash Flow as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/685f6325-478f-40e0-a3ef-c96a3dbd93d3/chart/dcf?date=2026-02-27\" width=\"746\"/></a><figcaption>CRMD Discounted Cash Flow as at Feb 2026</figcaption></figure> <p><a class=\"company-report-links\" data-vars-link-type=\"dcf_explainer_cta\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crmd/cormedix/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for CorMedix.</a></p> <h3>Approach 2: CorMedix Price vs Earnings</h3> <p>For a company that has positive earnings, the P/E ratio is a straightforward way to think about what you are paying for each dollar of profit. It helps you compare CorMedix with other businesses that also generate earnings in the same sector.</p> <p>A higher or lower P/E often reflects what the market expects for future growth and how risky those earnings might be. Higher expected growth and lower perceived risk can support a higher ‚Äúnormal‚Äù P/E, while lower growth expectations or higher risk can justify a lower one.</p> <p>CorMedix currently trades on a P/E of 3.56x. That is below the Pharmaceuticals industry average of 19.89x and below the peer average of 9.43x. Simply Wall St also calculates a ‚ÄúFair Ratio‚Äù for CorMedix of 15.70x, which is an estimate of what the P/E might be given factors such as its earnings profile, industry, profit margins, market cap and specific risks.</p> <p>This Fair Ratio aims to be more tailored than a simple comparison with peers or the industry because it adjusts for growth characteristics, risk and profitability instead of assuming all companies deserve the same multiple. When you compare CorMedix‚Äôs current P/E of 3.56x with the Fair Ratio of 15.70x, the shares screen as undervalued on this metric.</p> <p><strong>Result: UNDERVALUED</strong></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/pharmaceuticals-biotech/nasdaq-crmd/cormedix/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NasdaqGM:CRMD P/E Ratio as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/685f6325-478f-40e0-a3ef-c96a3dbd93d3/chart/pe-multiple-vs-industry?date=2026-02-27\" width=\"746\"/></a><figcaption>NasdaqGM:CRMD P/E Ratio as at Feb 2026</figcaption></figure> <p>P/E ratios tell one story, but what if the real opportunity lies elsewhere? <a class=\"company-report-links\" data-vars-link-type=\"cta_preferred_multiple_contextual\" href=\"https://simplywall.st/discover/investing-ideas/473625/top-founder-led-companies/us\" rel=\"noopener noreferrer\" target=\"_blank\">Start investing in legacies, not executives. Discover our 19 top founder-led companies</a>.</p> <h3>Upgrade Your Decision Making: Choose your CorMedix Narrative</h3> <p>Earlier we mentioned that there is an even better way to understand valuation, so on Simply Wall St you can use Narratives, which let you spell out the story you believe about CorMedix, link that story to specific revenue, earnings and margin forecasts, and then see a Fair Value that updates automatically as new news or earnings arrive on the Community page used by millions of investors. This can help you compare that Fair Value with today‚Äôs price and decide if CorMedix at, say, a more bullish US$22.00 view or a more cautious US$14.00 view is closer to your own expectations.</p> <p>Do you think there's more to the story for CorMedix? <a class=\"company-report-links\" data-vars-link-type=\"cta_create_narrative_community\" href=\"https://simplywall.st/stock/NasdaqGM/CRMD\" rel=\"noopener noreferrer\" target=\"_blank\">Head over to our Community to see what others are saying!</a></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/pharmaceuticals-biotech/nasdaq-crmd/cormedix\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NasdaqGM:CRMD 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/685f6325-478f-40e0-a3ef-c96a3dbd93d3/chart/quote-price?date=2026-02-27\" width=\"746\"/></a><figcaption>NasdaqGM:CRMD 1-Year Stock Price Chart</figcaption></figure> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><p>‚Ä¢ Dividend Powerhouses (3%+ Yield)<br/>‚Ä¢ Undervalued Small Caps with Insider Buying<br/>‚Ä¢ High growth Tech and AI Companies<br/><br/>Or build your own from over 50 metrics.</p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/stock-screener\" target=\"_blank\">Explore Now for Free</a></div></div>",
            "pub_date": "2026-02-28 01:21:20",
            "link": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crmd/cormedix/news/is-cormedix-crmd-pricing-reflect-recent-share-weakness-or-fu",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Should Northern Trust's New AI Hedging and CLO Services Strategy Prompt Action From NTRS Investors?",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>In recent weeks, Northern Trust expanded its CLO middle-office services on the Omnium platform and broadened its dynamic currency hedging framework by adding Berenberg‚Äôs AI-based models, giving institutional clients more sophisticated compliance, waterfall calculation, and currency risk management options across major global markets.</li> <li>Together, these moves highlight Northern Trust‚Äôs emphasis on technology-enabled, fee-based services that aim to enhance operational efficiency and risk management for asset owners and asset managers.</li> <li>Next, we‚Äôll explore how the addition of AI-driven currency hedging and enhanced CLO servicing could reshape Northern Trust‚Äôs investment narrative.</li> </ul><p>The future of work is here. Discover the <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/473746/robotics-andamp-automation-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">29 top robotics and automation stocks</a> leading the charge in AI-driven automation and industrial transformation.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Northern Trust Investment Narrative Recap</h2><p>Northern Trust‚Äôs appeal rests on its ability to compound fee-based income while keeping costs and risks under control, even as revenue growth trails the wider market. The latest CLO and AI currency hedging upgrades support that services-led story, but do not fundamentally change the near-term picture where slower expected earnings growth and pressure on margins remain key issues to watch.</p> <p>Among recent announcements, the expanded CLO middle-office services on the Omnium platform look most relevant, because they align with Northern Trust‚Äôs push to deepen relationships with complex asset managers. If these offerings help defend fee pools and support operating efficiency, they may partially offset the risk that modest revenue growth, rising expenses, or competitive pressure leaves returns on equity and profit growth below investor expectations.</p> <p>Yet behind these technology wins, investors should also be aware of...</p> <p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/diversified-financials/nasdaq-ntrs/northern-trust/qqtlltpw-fee-headwinds-and-market-shifts-will-shape-margins-in-coming-quarters\" rel=\"noopener noreferrer\" target=\"_blank\">Read the full narrative on Northern Trust (it's free!)</a></p><p>Northern Trust's narrative projects $8.2 billion revenue and $1.4 billion earnings by 2028.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/diversified-financials/nasdaq-ntrs/northern-trust/qqtlltpw-fee-headwinds-and-market-shifts-will-shape-margins-in-coming-quarters\" rel=\"noopener noreferrer\" target=\"_blank\">Uncover how Northern Trust's forecasts yield a $157.11 fair value</a>, a 6% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/us/diversified-financials/nasdaq-ntrs/northern-trust\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NTRS 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/a87509c2-2599-4108-bf2b-e61b0678e533/chart/quote-price\" width=\"746\"/></a><figcaption>NTRS 1-Year Stock Price Chart</figcaption></figure> <p>Three fair value estimates from the Simply Wall St Community span from about US$156 to over US$254,541 per share, showing how far opinions can spread. Set against this, the core catalyst of technology-enabled, fee-based services and the risk of slower earnings growth than the wider market give you important context for assessing which narratives about Northern Trust‚Äôs future you find most convincing.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/diversified-financials/nasdaq-ntrs/northern-trust\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 3 other fair value estimates on Northern Trust</a> - why the stock might be worth just $156.54!</p><h2>The Verdict Is Yours</h2><p>Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.</p><ul><li>A great starting point for your Northern Trust research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/diversified-financials/nasdaq-ntrs/northern-trust\" rel=\"noopener noreferrer\" target=\"_blank\">3 key rewards and 1 important warning sign</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/diversified-financials/nasdaq-ntrs/northern-trust\" rel=\"noopener noreferrer\" target=\"_blank\">Our free Northern Trust research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Northern Trust's overall financial health at a glance.</li></ul><h2>Interested In Other Possibilities?</h2><p>The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:</p><ul><li>Invest in the nuclear renaissance through our list of <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473644/nuclear-renaissance/global\" rel=\"noopener noreferrer\" target=\"_blank\">84 elite nuclear energy infrastructure plays</a> powering the global AI revolution.</li><li>Find <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">54 companies with promising cash flow potential yet trading below their fair value</a>.</li><li>The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434414/ai-penny-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">23 smaller AI-focused companies with strong growth potential</a> through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\">Valuation is complex, but we're here to simplify it.</h3><p>Discover if Northern Trust might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"/stocks/us/diversified-financials/nasdaq-ntrs/northern-trust/valuation\" target=\"_blank\">Access Free Analysis</a></div></div>",
            "pub_date": "2026-02-28 01:21:20",
            "link": "https://simplywall.st/stocks/us/diversified-financials/nasdaq-ntrs/northern-trust/news/should-northern-trusts-new-ai-hedging-and-clo-services-strat",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "What Viking Holdings (VIK)'s New 2027 U.S. River Cruise Itineraries Mean For Shareholders",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>In February 2026, Viking¬Æ announced that bookings are open for several new 2027 itineraries on the Mississippi and Ohio rivers, including 8-, 15-, and 22-day destination-focused cruises between New Orleans, Memphis, Louisville, St. Louis, and St. Paul.</li> <li>By deepening its focus on culturally rich American river routes, spanning Civil War sites, musical heritage, and regional cuisine, Viking is broadening its appeal to experience-driven travelers seeking immersive itineraries.</li> <li>We‚Äôll now examine how Viking‚Äôs expansion of Mississippi and Ohio river sailings could influence its investment narrative built around heritage experiences.</li> </ul><p>Invest in the nuclear renaissance through our list of <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/473644/nuclear-renaissance/global\" rel=\"noopener noreferrer\" target=\"_blank\">84 elite nuclear energy infrastructure plays</a> powering the global AI revolution.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Viking Holdings Investment Narrative Recap</h2><p>To own Viking, you need to believe in its ability to turn an expanding portfolio of culturally rich itineraries into durable demand and healthy margins, while managing high debt and cost pressures. The new Mississippi and Ohio river sailings strengthen the near term catalyst of strong advance bookings by adding more heritage-led product in the key U.S. market, but they do not materially change the biggest current risk around elevated leverage and exposure to older, premium travelers.</p> <p>Among recent announcements, the multi year marketing partnership with the PGA TOUR through 2030 is especially relevant. Together with the new Mississippi and Ohio cruises, it reinforces Viking‚Äôs push into the U.S., supporting the catalyst of capacity expansion into new geographies and potentially helping sustain strong booking trends that analysts are watching ahead of the upcoming Q4 2025 results on March 3, 2026.</p> <p>Yet beneath the appeal of Viking‚Äôs new itineraries, investors should also be aware of how its high debt and older customer base could...</p> <p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/consumer-services/nyse-vik/viking-holdings/ty502cz7-global-expansion-will-unlock-premium-travel-experiences-7q8c\" rel=\"noopener noreferrer\" target=\"_blank\">Read the full narrative on Viking Holdings (it's free!)</a></p><p>Viking Holdings' narrative projects $8.5 billion revenue and $2.0 billion earnings by 2028. This requires 13.6% yearly revenue growth and about a $1.3 billion earnings increase from $694.2 million today.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/consumer-services/nyse-vik/viking-holdings/ty502cz7-global-expansion-will-unlock-premium-travel-experiences-7q8c\" rel=\"noopener noreferrer\" target=\"_blank\">Uncover how Viking Holdings' forecasts yield a $74.06 fair value</a>, a 7% downside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/us/consumer-services/nyse-vik/viking-holdings\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"VIK 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/4bd8946f-41e1-46d9-8eb2-91286843a6af/chart/quote-price\" width=\"746\"/></a><figcaption>VIK 1-Year Stock Price Chart</figcaption></figure> <p>Some of the most optimistic analysts were already expecting Viking to reach about US$8.9 billion in revenue and US$2.2 billion in earnings by 2028, which is a far more upbeat view than the baseline narrative and assumes that advantages like prime river access translate into much stronger growth, so you should weigh this against the new Mississippi and Ohio routes and consider how both optimistic and more cautious theses might evolve from here.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/consumer-services/nyse-vik/viking-holdings\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 5 other fair value estimates on Viking Holdings</a> - why the stock might be worth less than half the current price!</p><h2>The Verdict Is Yours</h2><p>Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.</p><ul><li>A great starting point for your Viking Holdings research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/consumer-services/nyse-vik/viking-holdings\" rel=\"noopener noreferrer\" target=\"_blank\">3 key rewards and 1 important warning sign</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/consumer-services/nyse-vik/viking-holdings\" rel=\"noopener noreferrer\" target=\"_blank\">Our free Viking Holdings research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Viking Holdings' overall financial health at a glance.</li></ul><h2>Ready To Venture Into Other Investment Styles?</h2><p>These stocks are moving-our analysis flagged them today. Act fast before the price catches up:</p><ul><li>Uncover the next big thing with <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/472945/elite-penny-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">30 elite penny stocks</a> that balance risk and reward.</li><li>The latest GPUs need a type of rare earth metal called Terbium and there are only <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434418/rare-earth-metal-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">31 companies in the world exploring or producing it</a>. Find the list for free.</li><li>AI is about to change healthcare. These <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434426/healthcare-ai/us\" rel=\"noopener noreferrer\" target=\"_blank\">29 stocks are working on everything from early diagnostics to drug discovery</a>. The best part - they are all under $10b in market cap - there's still time to get in early.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-02-28 01:16:08",
            "link": "https://simplywall.st/stocks/us/consumer-services/nyse-vik/viking-holdings/news/what-viking-holdings-viks-new-2027-us-river-cruise-itinerari",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "How Investors May Respond To Sunrun (RUN) Profit Swing and Surging Home Storage Adoption",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>Sunrun Inc. has reported its fourth-quarter and full-year 2025 results, with sales reaching US$466.49¬†million for the quarter and US$1.82¬†billion for the year, revenue of US$1.16¬†billion for the quarter and US$2.96¬†billion for the year, and a swing from a multi‚Äëbillion‚Äëdollar net loss in 2024 to net income of US$103.57¬†million for the quarter and US$449.95¬†million for 2025.</li> <li>Beyond the earnings beat, Sunrun‚Äôs growing battery footprint, now more than 217,000 residential systems and a 71% storage attachment rate, underpins its expanding role in grid services, highlighted by a successful distributed power plant season with PG&amp;E that achieved nearly 99% dispatch accuracy across over 1,200 hours.</li> <li>We‚Äôll now examine how Sunrun‚Äôs sharp turnaround to profitability and rising storage attachment rates might reshape its existing investment narrative.</li> </ul><p>Capitalize on the AI infrastructure supercycle with our selection of the <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/473744/ai-infrastructure-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">33 best 'picks and shovels' of the AI gold rush</a> converting record-breaking demand into massive cash flow.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Sunrun Investment Narrative Recap</h2><p>To own Sunrun, you need to believe residential solar plus storage can remain attractive even as tax credits phase out and financing stays complex. The latest earnings beat and return to profitability strengthen the case that scale and higher storage attachment can support margins, but the biggest near term swing factor is still access to affordable capital, while long term policy uncertainty around incentives remains a key overhang. This quarter‚Äôs results do not remove those risks, but they do improve Sunrun‚Äôs financial footing.</p> <p>The most relevant recent development is Sunrun‚Äôs completion of the PG&amp;E Local PeakShift Power season, where over 1,000 customer systems delivered nearly 1,200 hours of highly accurate dispatch. Paired with storage attachment rates reaching 71% by year end 2025, this grid services performance gives more substance to the idea that batteries and virtual power plants could become a meaningful earnings driver, potentially offsetting some pressure from expiring tax credits and higher financing costs over time.</p> <p>Yet while the profit rebound is encouraging, investors should also be aware that concentrated policy risk around solar tax credits could still...</p> <p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/capital-goods/nasdaq-run/sunrun/puusfyum-run-supportive-policy-changes-and-market-demand-will-drive-mixed-outcomes-ahead\" rel=\"noopener noreferrer\" target=\"_blank\">Read the full narrative on Sunrun (it's free!)</a></p><p>Sunrun's narrative projects $2.9 billion revenue and $465.4 million earnings by 2028.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/capital-goods/nasdaq-run/sunrun/puusfyum-run-supportive-policy-changes-and-market-demand-will-drive-mixed-outcomes-ahead\" rel=\"noopener noreferrer\" target=\"_blank\">Uncover how Sunrun's forecasts yield a $22.74 fair value</a>, a 11% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/us/capital-goods/nasdaq-run/sunrun\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"RUN 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/9fa2a4c7-de78-47ca-906e-c5edae8a6116/chart/quote-price\" width=\"746\"/></a><figcaption>RUN 1-Year Stock Price Chart</figcaption></figure> <p>Before this surprise profit, the most bearish analysts assumed almost flat revenue growth near US$2.1 billion and no profitability, so their far more cautious view of Sunrun‚Äôs financing and policy risks may shift meaningfully as investors reassess those assumptions.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/capital-goods/nasdaq-run/sunrun\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 5 other fair value estimates on Sunrun</a> - why the stock might be worth as much as 32% more than the current price!</p><h2>The Verdict Is Yours</h2><p>Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.</p><ul><li>A great starting point for your Sunrun research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/capital-goods/nasdaq-run/sunrun\" rel=\"noopener noreferrer\" target=\"_blank\">2 key rewards and 2 important warning signs</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/capital-goods/nasdaq-run/sunrun\" rel=\"noopener noreferrer\" target=\"_blank\">Our free Sunrun research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Sunrun's overall financial health at a glance.</li></ul><h2>No Opportunity In Sunrun?</h2><p>Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:</p><ul><li>The future of work is here. Discover the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473746/robotics-andamp-automation-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">29 top robotics and automation stocks</a> leading the charge in AI-driven automation and industrial transformation.</li><li>Uncover the next big thing with <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/472945/elite-penny-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">30 elite penny stocks</a> that balance risk and reward.</li><li>Explore <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/282/quantum-computing-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">23 top quantum computing companies</a> leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-02-28 01:16:08",
            "link": "https://simplywall.st/stocks/us/capital-goods/nasdaq-run/sunrun/news/how-investors-may-respond-to-sunrun-run-profit-swing-and-sur",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "The Bull Case For Amneal Pharmaceuticals (AMRX) Could Change Following New 2026 Revenue Guidance Release",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>Amneal Pharmaceuticals recently issued 2026 earnings guidance, projecting net revenue between US$3.05¬†billion and US$3.15¬†billion, alongside heightened attention around its latest quarterly earnings release.</li> <li>This new guidance gives investors a clearer view of management‚Äôs expectations for the scale of Amneal‚Äôs business as it expands across generics, injectables, biosimilars, and specialty products.</li> <li>We‚Äôll now examine how Amneal‚Äôs US$3.05‚Äì3.15¬†billion 2026 revenue outlook may influence the existing investment narrative built around diversification.</li> </ul><p>We've uncovered the <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/473528/dividend-fortresses/us\" rel=\"noopener noreferrer\" target=\"_blank\">15 dividend fortresses</a> yielding 5%+ that don't just survive market storms, but thrive in them.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Amneal Pharmaceuticals Investment Narrative Recap</h2><p>To own Amneal, you need to believe its push across generics, injectables, biosimilars, and specialty products can offset pricing pressure and legal costs while supporting sustainable scale. The new 2026 revenue guidance of US$3.05‚Äì3.15 billion reinforces that diversification story but does not materially change the near term focus on execution in higher margin categories or the key risk around ongoing pricing and regulatory pressures.</p> <p>The most relevant recent announcement here is the nationwide opioids settlement, which commits Amneal to up to US$88.5 million in cash payments and up to US$177.4 million in naloxone product. That settlement helps clarify a major legal overhang just as management is asking investors to weigh its revenue outlook and pipeline against elevated leverage and the cost of maintaining compliance and quality across a broad portfolio.</p> <p>Yet behind this clearer revenue outlook and legal visibility, investors should still be aware of...</p> <p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-amrx/amneal-pharmaceuticals/3tt90axt-amrx-recent-fda-approvals-and-pipeline-launches-will-drive-upside-momentum\" rel=\"noopener noreferrer\" target=\"_blank\">Read the full narrative on Amneal Pharmaceuticals (it's free!)</a></p><p>Amneal Pharmaceuticals‚Äô narrative projects $3.5 billion revenue and $207.9 million earnings by 2028.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-amrx/amneal-pharmaceuticals/3tt90axt-amrx-recent-fda-approvals-and-pipeline-launches-will-drive-upside-momentum\" rel=\"noopener noreferrer\" target=\"_blank\">Uncover how Amneal Pharmaceuticals' forecasts yield a $15.20 fair value</a>, a 5% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amrx/amneal-pharmaceuticals\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"AMRX 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/de8755ce-faf4-4170-8a24-89d67d81be0e/chart/quote-price\" width=\"746\"/></a><figcaption>AMRX 1-Year Stock Price Chart</figcaption></figure> <p>Three fair value estimates from the Simply Wall St Community span roughly US$11.94 to about US$70 per share, showing how far apart individual views on Amneal‚Äôs potential can be. Against that backdrop, Amneal‚Äôs new 2026 revenue guidance invites you to weigh its diversification catalyst alongside ongoing pricing and regulatory risks that could influence how those projections translate into business performance.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-amrx/amneal-pharmaceuticals\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 3 other fair value estimates on Amneal Pharmaceuticals</a> - why the stock might be worth over 4x more than the current price!</p><h2>Form Your Own Verdict</h2><p>Don't just follow the ticker - dig into the data and build a conviction that's truly your own.</p><ul><li>A great starting point for your Amneal Pharmaceuticals research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amrx/amneal-pharmaceuticals\" rel=\"noopener noreferrer\" target=\"_blank\">4 key rewards and 3 important warning signs</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amrx/amneal-pharmaceuticals\" rel=\"noopener noreferrer\" target=\"_blank\">Our free Amneal Pharmaceuticals research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Amneal Pharmaceuticals' overall financial health at a glance.</li></ul><h2>Ready For A Different Approach?</h2><p>Opportunities like this don't last. These are today's most promising picks. Check them out now:</p><ul><li>Capitalize on the AI infrastructure supercycle with our selection of the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473744/ai-infrastructure-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">33 best 'picks and shovels' of the AI gold rush</a> converting record-breaking demand into massive cash flow.</li><li>The latest GPUs need a type of rare earth metal called Dysprosium and there are only <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434418/rare-earth-metal-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">31 companies in the world exploring or producing it</a>. Find the list for free.</li><li>This technology could replace computers: discover <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/282/quantum-computing-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">23 stocks that are working to make quantum computing a reality</a>.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-02-28 01:16:08",
            "link": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-amrx/amneal-pharmaceuticals/news/the-bull-case-for-amneal-pharmaceuticals-amrx-could-change-f-3",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Is National Energy Services Reunited (NESR) Share Surge Justified By Recent Valuation Signals",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>This article is designed to help you assess whether National Energy Services Reunited still represents good value after its recent share price run, or whether the excitement has moved ahead of the company‚Äôs fundamentals.</li> <li>The stock last closed at US$25.14, with returns of 3.9% over 7 days, 26.0% over 30 days, 59.2% year to date and 207.7% over the past year, as well as 278.6% over 3 years and 95.0% over 5 years.</li> <li>These moves have put the company on more investors' radar, and they have been looking more closely at how its current price lines up with its underlying worth. That is where a structured valuation review comes in, using multiple methods to see whether the recent share price action still matches the fundamentals.</li> <li>On our Simply Wall St checks, National Energy Services Reunited scores 2 out of 6 on valuation, which you can see in detail in our <a class=\"company-report-links\" href=\"https://www.simplywall.st/stocks/us/energy/nasdaq-nesr/national-energy-services-reunited/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">valuation scorecard</a>. Next we will walk through the different ways investors commonly assess value, before finishing with a more complete way to think about valuation as a whole.</li> </ul> <p>National Energy Services Reunited scores just 2/6 on our valuation checks. See what other red flags we found in the <a class=\"company-report-links\" data-vars-link-type=\"cta_low_value_score\" href=\"https://www.simplywall.st/stocks/us/energy/nasdaq-nesr/national-energy-services-reunited/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">full valuation breakdown</a>.</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Approach 1: National Energy Services Reunited Discounted Cash Flow (DCF) Analysis</h2> <p>A Discounted Cash Flow, or DCF, model takes the cash that a company is expected to generate in the future and discounts it back to today to estimate what the entire business could be worth now.</p> <p>For National Energy Services Reunited, the latest twelve month Free Cash Flow is about $153.0 million. The model used here is a 2 Stage Free Cash Flow to Equity approach, which first applies analyst forecasts and then extends those cash flows further out using additional assumptions by Simply Wall St.</p> <p>The projections used in the model include Free Cash Flow of $154.6 million in 2026 and $219.0 million in 2028, with further years out to 2035 based on extrapolated estimates, all in $. When these projected cash flows are discounted back to today, the DCF model arrives at an estimated intrinsic value of about $58.38 per share.</p> <p>Compared with the recent share price of $25.14, this DCF estimate suggests a difference of around 56.9% between the modelled intrinsic value and the current market price.</p> <p><strong>Result: UNDERVALUED (based on this DCF model)</strong></p> <p>Our Discounted Cash Flow (DCF) analysis suggests National Energy Services Reunited is undervalued by 56.9%. Track this in your <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_undervalued\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_undervalued\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a>, or discover <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">54 more high quality undervalued stocks</a>.</p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/energy/nasdaq-nesr/national-energy-services-reunited/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NESR Discounted Cash Flow as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/7f4533ec-72e9-4bee-b095-b8fa053aca99/chart/dcf?date=2026-02-27\" width=\"746\"/></a><figcaption>NESR Discounted Cash Flow as at Feb 2026</figcaption></figure> <p><a class=\"company-report-links\" data-vars-link-type=\"dcf_explainer_cta\" href=\"https://www.simplywall.st/stocks/us/energy/nasdaq-nesr/national-energy-services-reunited/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for National Energy Services Reunited.</a></p> <h2>Approach 2: National Energy Services Reunited Price vs Earnings</h2> <p>For a profitable company, the P/E ratio is a straightforward way to see how much you are paying for each dollar of earnings. This makes it a useful cross check alongside a DCF model. What counts as a ‚Äúnormal‚Äù P/E depends on what the market expects for future earnings growth and how risky those earnings are, with higher expected growth or lower perceived risk usually supporting a higher multiple.</p> <p>National Energy Services Reunited currently trades on a P/E of about 49.6x. That sits above both the Energy Services industry average of roughly 26.6x and the peer group average of about 32.7x. This suggests the market is applying a richer multiple than these broad comparison points.</p> <p>Simply Wall St‚Äôs Fair Ratio for the stock is 25.9x. This is a proprietary estimate of what the P/E might be based on factors such as earnings growth, profit margins, industry, market cap and company specific risks. Because it ties the multiple to these fundamentals, the Fair Ratio can offer a more tailored reference point than a simple peer or industry comparison.</p> <p>When set against the current P/E of 49.6x, the Fair Ratio of 25.9x points to the shares trading on a higher multiple than this framework would suggest.</p> <p><strong>Result: OVERVALUED</strong></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/energy/nasdaq-nesr/national-energy-services-reunited/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NasdaqCM:NESR P/E Ratio as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/7f4533ec-72e9-4bee-b095-b8fa053aca99/chart/pe-multiple-vs-industry?date=2026-02-27\" width=\"746\"/></a><figcaption>NasdaqCM:NESR P/E Ratio as at Feb 2026</figcaption></figure> <p>P/E ratios tell one story, but what if the real opportunity lies elsewhere? <a class=\"company-report-links\" data-vars-link-type=\"cta_preferred_multiple_contextual\" href=\"https://simplywall.st/discover/investing-ideas/473625/top-founder-led-companies/us\" rel=\"noopener noreferrer\" target=\"_blank\">Start investing in legacies, not executives. Discover our 19 top founder-led companies</a>.</p> <h3>Upgrade Your Decision Making: Choose your National Energy Services Reunited Narrative</h3> <p>Earlier we mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you set out your story for National Energy Services Reunited, link that story to a forecast for revenue, earnings and margins, and then see the Fair Value that falls out of those assumptions so you can compare it with the current share price.</p> <p>Instead of only relying on a single P/E or DCF number, a Narrative combines your view of the business with a live model. It updates automatically when new earnings or news arrive, and is available on the Community page where millions of investors share their own versions.</p> <p>For example, one National Energy Services Reunited Narrative might align with the bullish analyst fair value of US$30.00, built around confidence in hydraulic fracturing capacity and MENA contracts. Another could sit nearer the cautious US$10.00 view that focuses on regional concentration and energy transition risks. Seeing those side by side can help you decide whether the current US$25.14 price is above or below the story you find most convincing.</p> <p>For National Energy Services Reunited, here are previews of two leading National Energy Services Reunited narratives that may help frame the discussion:</p> <p><a href=\"/us/energy/nasdaq-nesr/national-energy-services-reunited/lj4o0x5w-rising-mena-demand-will-boost-oilfield-service-expansion-mfij?utm_medium=finance_user&amp;utm_campaign=cta_bull_narrative_link&amp;utm_source=post\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong>üêÇ National Energy Services Reunited Bull Case</strong></a></p> <p>Fair value in this bullish narrative: US$30.00 per share</p> <p>Current price vs this fair value: about 16.1% below the narrative fair value</p> <p>Assumed revenue growth used in this narrative: 19.65% a year</p> <ul> <li>Supports a higher fair value case built around hydraulic fracturing scale in Saudi Arabia, contract visibility across MENA and higher profit margins tied to technology and efficiency gains.</li> <li>Assumes National Energy Services Reunited can sustain robust revenue growth and margin expansion, with future earnings and P/E considered consistent with a US$30.00 anchor valuation.</li> <li>Notes meaningful risks from oilfield concentration, regional exposure and capital intensity, so the optimistic outcome still depends on execution and stable operating conditions.</li> </ul> <p><a href=\"/us/energy/nasdaq-nesr/national-energy-services-reunited/1sh65zqm-revenue-recovery-and-sector-rebound-will-drive-long-term-shareholder-returns?utm_medium=finance_user&amp;utm_campaign=cta_bear_narrative_link&amp;utm_source=post\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong>üêª National Energy Services Reunited Bear Case</strong></a></p> <p>Fair value in this more cautious narrative: US$22.14 per share</p> <p>Current price vs this fair value: about 13.5% above the narrative fair value</p> <p>Assumed revenue growth used in this narrative: 18.93% a year</p> <ul> <li>Frames the story around solid MENA contracts and Jafurah exposure, but anchors fair value closer to US$22.14, even with updated analyst targets around US$30.</li> <li>Builds in steady revenue growth and margin improvement, while assuming a more modest future P/E multiple compared with the bullish view.</li> <li>Highlights contract concentration, capital demands, working capital strain and long term energy transition as key risks that could keep the share price nearer this fair value.</li> </ul> <p>Viewed together, these narratives provide two different sets of assumptions for National Energy Services Reunited that can be compared with the current US$25.14 share price.</p> <p>Do you think there's more to the story for National Energy Services Reunited? <a class=\"company-report-links\" data-vars-link-type=\"cta_create_narrative_community\" href=\"https://simplywall.st/stock/NasdaqCM/NESR\" rel=\"noopener noreferrer\" target=\"_blank\">Head over to our Community to see what others are saying!</a></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/energy/nasdaq-nesr/national-energy-services-reunited\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NasdaqCM:NESR 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/7f4533ec-72e9-4bee-b095-b8fa053aca99/chart/quote-price?date=2026-02-27\" width=\"746\"/></a><figcaption>NasdaqCM:NESR 1-Year Stock Price Chart</figcaption></figure> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\">Valuation is complex, but we're here to simplify it.</h3><p>Discover if National Energy Services Reunited might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"/stocks/us/energy/nasdaq-nesr/national-energy-services-reunited/valuation\" target=\"_blank\">Access Free Analysis</a></div></div>",
            "pub_date": "2026-02-28 01:16:08",
            "link": "https://simplywall.st/stocks/us/energy/nasdaq-nesr/national-energy-services-reunited/news/is-national-energy-services-reunited-nesr-share-surge-justif",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Why Mesoblast (ASX:MSB) Is Down 7.1% After Issuing First Detailed Ryoncil Revenue Guidance",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>Mesoblast Limited recently reported half-year 2025 results, with revenue rising to US$51.34 million and net loss and loss per share both narrowing, and subsequently issued fiscal 2026 guidance calling for US$110 million to US$120 million in Ryoncil net revenue.</li> <li>This combination of sharply higher reported revenue and the first detailed full-year outlook for Ryoncil offers investors a clearer view of Mesoblast‚Äôs early commercial trajectory and cost profile.</li> <li>We‚Äôll now examine how Mesoblast‚Äôs new Ryoncil revenue guidance reframes its investment narrative built around cell therapy commercialization and pipeline expansion.</li> </ul><p>Rare earth metals are the new gold rush. Find out which <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/434418/rare-earth-metal-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">31 stocks are leading the charge</a>.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Mesoblast Investment Narrative Recap</h2><p>To own Mesoblast today, you need to believe that Ryoncil can scale from a niche pediatric GvHD launch into a broader cell therapy franchise while the company manages ongoing losses and funding needs. The sharp step up in reported revenue and the new US$110 million to US$120 million Ryoncil guidance sharpen the focus on near term execution: can demand ramp fast enough to ease cash burn, and will trial and regulatory timelines hold without costly delays?</p> <p>The half year 2025 results are the most relevant recent announcement here, because they show early financial traction alongside continuing losses. Revenue of US$51.34 million and a reduced but still sizeable net loss of US$40.16 million underscore the tension between growing top line and the risk that R&amp;D and commercial spend remain high if label expansions in adult GvHD, inflammatory bowel disease or chronic low back pain take longer than expected to translate into meaningful sales.</p> <p>Yet against this improving revenue picture, the risk that slower Ryoncil uptake or trial delays could still force fresh capital raises is something investors should be aware of...</p> <p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/tz4l8krr-update-for-mesoblast\" rel=\"noopener noreferrer\" target=\"_blank\">Read the full narrative on Mesoblast (it's free!)</a></p><p>Mesoblast's narrative projects $485.4 million revenue and $222.1 million earnings by 2029. This requires 204.5% yearly revenue growth and a $324.2 million earnings increase from -$102.1 million today.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/tz4l8krr-update-for-mesoblast\" rel=\"noopener noreferrer\" target=\"_blank\">Uncover how Mesoblast's forecasts yield a A$3.83 fair value</a>, a 71% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"ASX:MSB 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/600844ad-7b8f-4b60-be67-41aeee6634b3/chart/quote-price\" width=\"746\"/></a><figcaption>ASX:MSB 1-Year Stock Price Chart</figcaption></figure> <p>The more optimistic analysts were already assuming revenue could reach about US$1.1 billion and earnings about US$585 million by 2028, so compared with the more cautious concerns about cash burn and trial risk, their narrative is far more bullish and you should recognize that views on Mesoblast can differ widely and may shift again after this new Ryoncil guidance.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 17 other fair value estimates on Mesoblast</a> - why the stock might be a potential multi-bagger!</p><h2>The Verdict Is Yours</h2><p>Don't just follow the ticker - dig into the data and build a conviction that's truly your own.</p><ul><li>A great starting point for your Mesoblast research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares\" rel=\"noopener noreferrer\" target=\"_blank\">3 key rewards and 1 important warning sign</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares\" rel=\"noopener noreferrer\" target=\"_blank\">Our free Mesoblast research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Mesoblast's overall financial health at a glance.</li></ul><h2>Interested In Other Possibilities?</h2><p>Opportunities like this don't last. These are today's most promising picks. Check them out now:</p><ul><li>The future of work is here. Discover the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473746/robotics-andamp-automation-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">29 top robotics and automation stocks</a> leading the charge in AI-driven automation and industrial transformation.</li><li>Invest in the nuclear renaissance through our list of <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473644/nuclear-renaissance/global\" rel=\"noopener noreferrer\" target=\"_blank\">84 elite nuclear energy infrastructure plays</a> powering the global AI revolution.</li><li>AI is about to change healthcare. These <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434426/healthcare-ai/au\" rel=\"noopener noreferrer\" target=\"_blank\">10 stocks are working on everything from early diagnostics to drug discovery</a>. The best part - they are all under $10b in market cap - there's still time to get in early.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-02-28 01:10:51",
            "link": "https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/why-mesoblast-asxmsb-is-down-71-after-issuing-first-detailed",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Why ServiceTitan (TTAN) Is Up 10.5% After Morgan Stanley Names It A Sector Top Pick",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>In recent weeks, ServiceTitan was highlighted by Wall Street analysts as one of the best beaten down technology names, with Morgan Stanley upgrading it to Overweight and naming it a sector top pick while institutional investors such as Artisan increased their holdings following earlier software weakness.</li> <li>These moves underscore growing institutional and analyst confidence in ServiceTitan‚Äôs vertical software model for trades and its potential to expand across additional end markets and product lines.</li> <li>We‚Äôll now examine how this renewed analyst and institutional confidence, especially Morgan Stanley‚Äôs sector top pick call, could influence ServiceTitan‚Äôs investment narrative.</li> </ul><p>Capitalize on the AI infrastructure supercycle with our selection of the <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/473744/ai-infrastructure-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">33 best 'picks and shovels' of the AI gold rush</a> converting record-breaking demand into massive cash flow.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>ServiceTitan Investment Narrative Recap</h2><p>To own ServiceTitan, you have to believe its vertical software can keep becoming the core system of record for trades while its AI, payments and MAX initiatives deepen customer reliance on the platform. The recent analyst upgrade and institutional buying may support sentiment around the near term catalyst of broader MAX and AI Pro adoption, but they do not remove the key risk that these agentic, automated workflows could prove harder for customers to implement at scale.</p> <p>Among recent announcements, the expansion of ServiceTitan‚Äôs AP Automation and fintech suite, including Tap to Pay and integrated financing, ties in most closely with the current bull thesis around usage based payments and higher take rates. If these tools see sustained customer adoption, they could reinforce the catalysts tied to payments and workflow automation that analysts are watching, even as questions about implementation complexity and returns on AI investments remain in focus.</p> <p>Yet behind the renewed optimism, investors should also be aware that the long term bet on AI driven automation and the MAX program could...</p> <p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/software/nasdaq-ttan/servicetitan/7pmj2q50-update-for-servicetitan\" rel=\"noopener noreferrer\" target=\"_blank\">Read the full narrative on ServiceTitan (it's free!)</a></p><p>ServiceTitan's narrative projects $1.5 billion revenue and $188.8 million earnings by 2028. This requires 18.4% yearly revenue growth and about a $486.9 million earnings increase from -$298.1 million today.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/software/nasdaq-ttan/servicetitan/7pmj2q50-update-for-servicetitan\" rel=\"noopener noreferrer\" target=\"_blank\">Uncover how ServiceTitan's forecasts yield a $136.33 fair value</a>, a 85% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/us/software/nasdaq-ttan/servicetitan\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"TTAN 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/254bf5df-024c-4f4c-b03f-feca2d584ec2/chart/quote-price\" width=\"746\"/></a><figcaption>TTAN 1-Year Stock Price Chart</figcaption></figure> <p>Five fair value estimates from the Simply Wall St Community span roughly US$38 to US$136 per share, showing how differently holders view ServiceTitan‚Äôs potential. Against that wide spread, the core debate around whether AI driven automation and MAX can deliver clear, scalable customer ROI becomes a key lens for thinking about the company‚Äôs longer term performance and invites you to compare several alternative viewpoints.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/software/nasdaq-ttan/servicetitan\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 5 other fair value estimates on ServiceTitan</a> - why the stock might be worth 48% less than the current price!</p><h2>Decide For Yourself</h2><p>Don't just follow the ticker - dig into the data and build a conviction that's truly your own.</p><ul><li>A great starting point for your ServiceTitan research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/software/nasdaq-ttan/servicetitan\" rel=\"noopener noreferrer\" target=\"_blank\">4 key rewards and 2 important warning signs</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/software/nasdaq-ttan/servicetitan\" rel=\"noopener noreferrer\" target=\"_blank\">Our free ServiceTitan research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate ServiceTitan's overall financial health at a glance.</li></ul><h2>Ready For A Different Approach?</h2><p>Our top stock finds are flying under the radar-for now. Get in early:</p><ul><li>The latest GPUs need a type of rare earth metal called Dysprosium and there are only <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434418/rare-earth-metal-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">31 companies in the world exploring or producing it</a>. Find the list for free.</li><li>Invest in the nuclear renaissance through our list of <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473644/nuclear-renaissance/global\" rel=\"noopener noreferrer\" target=\"_blank\">84 elite nuclear energy infrastructure plays</a> powering the global AI revolution.</li><li>We've uncovered the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473528/dividend-fortresses/us\" rel=\"noopener noreferrer\" target=\"_blank\">15 dividend fortresses</a> yielding 5%+ that don't just survive market storms, but thrive in them.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-02-28 01:10:51",
            "link": "https://simplywall.st/stocks/us/software/nasdaq-ttan/servicetitan/news/why-servicetitan-ttan-is-up-105-after-morgan-stanley-names-i",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Should Rising Analyst Optimism Around Earnings Shift On Holding‚Äôs (ONON) Long‚ÄëTerm Growth Narrative?",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>In recent days, On Holding attracted heightened attention as UBS and Zacks reiterated very positive views ahead of the company‚Äôs now-past 3 March 2026 earnings release, citing strong consumer momentum, solid revenue growth and earlier earnings surprises. </li> <li>This cluster of upbeat analyst commentary has sharpened focus on how On‚Äôs recent operational performance may be reshaping expectations for its long-term growth profile and profitability. </li> <li>Now, we‚Äôll examine how this rising analyst optimism around operational strength and upcoming results could influence On Holding‚Äôs existing investment narrative. </li> </ul><p>Uncover the next big thing with <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/472945/elite-penny-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">30 elite penny stocks</a> that balance risk and reward.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>On Holding Investment Narrative Recap</h2><p>To own On Holding, you need to believe its premium brand, product innovation and DTC focus can justify a high valuation and support durable growth. The immediate catalyst is the 3 March 2026 Q4 2025 earnings release, which sits at the center of the recent analyst optimism. The biggest near term risk is that expectations for continued revenue and earnings momentum are now elevated, so any disappointment could magnify share price volatility.</p> <p>The most relevant recent announcement is On‚Äôs 10 February 2026 confirmation of its Q4 2025 earnings date. With analysts already highlighting prior earnings surprises and solid revenue growth, this specific release has become a focal point for testing the bullish thesis on margins, DTC progress and international scaling. How the company‚Äôs reported sales and profitability compare with these expectations may either reinforce, or start to question, the current enthusiasm embedded in the shares.</p> <p>Yet beneath the upbeat commentary, the risk that heavy reliance on premium pricing could eventually face pushback is something investors should be aware of...</p> <p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/consumer-durables/nyse-onon/on-holding/pr8lhrz5-analyst-commentary-reveals-mixed-views-as-on-holding-adjusts-guidance-and-targets\" rel=\"noopener noreferrer\" target=\"_blank\">Read the full narrative on On Holding (it's free!)</a></p><p>On Holding‚Äôs narrative projects CHF5.0 billion revenue and CHF561.2 million earnings by 2028. This requires 22.9% yearly revenue growth and an earnings increase of about CHF425 million from CHF135.9 million today.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/consumer-durables/nyse-onon/on-holding/pr8lhrz5-analyst-commentary-reveals-mixed-views-as-on-holding-adjusts-guidance-and-targets\" rel=\"noopener noreferrer\" target=\"_blank\">Uncover how On Holding's forecasts yield a $61.90 fair value</a>, a 30% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/us/consumer-durables/nyse-onon/on-holding\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"ONON 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/30b460e6-f1a8-445d-9f78-310d4e375cd1/chart/quote-price\" width=\"746\"/></a><figcaption>ONON 1-Year Stock Price Chart</figcaption></figure> <p>Some of the most optimistic analysts were assuming revenue could climb toward CHF 5.5 billion and earnings to about CHF 725 million by 2028, which is far more upbeat than consensus and could be challenged if the recent focus on Asia Pacific expansion leaves results more exposed to regional slowdowns or shocks.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/consumer-durables/nyse-onon/on-holding\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 16 other fair value estimates on On Holding</a> - why the stock might be worth just $45.33!</p><h2>The Verdict Is Yours</h2><p>Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.</p><ul><li>A great starting point for your On Holding research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/consumer-durables/nyse-onon/on-holding\" rel=\"noopener noreferrer\" target=\"_blank\">3 key rewards</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/consumer-durables/nyse-onon/on-holding\" rel=\"noopener noreferrer\" target=\"_blank\">Our free On Holding research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate On Holding's overall financial health at a glance.</li></ul><h2>Contemplating Other Strategies?</h2><p>Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:</p><ul><li>Find <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">54 companies with promising cash flow potential yet trading below their fair value</a>.</li><li>We've uncovered the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473528/dividend-fortresses/us\" rel=\"noopener noreferrer\" target=\"_blank\">15 dividend fortresses</a> yielding 5%+ that don't just survive market storms, but thrive in them.</li><li>Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434418/rare-earth-metal-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">31 best rare earth metal stocks</a> of the very few that mine this essential strategic resource.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><p>‚Ä¢ Dividend Powerhouses (3%+ Yield)<br/>‚Ä¢ Undervalued Small Caps with Insider Buying<br/>‚Ä¢ High growth Tech and AI Companies<br/><br/>Or build your own from over 50 metrics.</p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/stock-screener\" target=\"_blank\">Explore Now for Free</a></div></div>",
            "pub_date": "2026-02-28 01:10:51",
            "link": "https://simplywall.st/stocks/us/consumer-durables/nyse-onon/on-holding/news/should-rising-analyst-optimism-around-earnings-shift-on-hold",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "SentinelOne Unveils Identity Platform As Market Weighs Losses And Valuation",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>SentinelOne (NYSE:S) has launched a next generation identity security platform focused on protecting both human users and AI agent accounts.</li> <li>The new offering shifts from traditional authentication checks to continuous, behavior based validation and runtime authorization withdrawal.</li> <li>The move targets rising identity centric threats as enterprises adopt more automation and AI driven workflows.</li> </ul> <p>SentinelOne enters this launch with shares at $13.48 and a mixed recent track record, including a 10.8% decline over the past 30 days and a 33.7% decline over the past year. For investors following NYSE:S, the new platform reflects how the company is trying to position itself in identity security as attack surfaces evolve.</p> <p>For investors and customers, the key question is how much demand develops for identity protection that explicitly includes AI agents alongside human users. This release also indicates where SentinelOne is focusing its product roadmap, which may influence how its role within broader cybersecurity exposure in a portfolio is evaluated.</p> <p>Stay updated on the most important news stories for <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://www.simplywall.st/stocks/us/software/nyse-s/sentinelone/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">SentinelOne</a> by adding it to your <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a>. Alternatively, explore our <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/stock/NYSE/S\" rel=\"noopener noreferrer\" target=\"_blank\">Community</a> to discover new perspectives on SentinelOne.</p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st/stocks/us/software/nyse-s/sentinelone/future\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NYSE:S Earnings &amp; Revenue Growth as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/f2abf38f-6e34-40bd-a59e-9d368e694ec3/chart/earnings-and-revenue-growth?date=2026-02-27\" width=\"746\"/></a><figcaption>NYSE:S Earnings &amp; Revenue Growth as at Feb 2026</figcaption></figure> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_news_risk_alert\" href=\"https://www.simplywall.st/stocks/us/software/nyse-s/sentinelone\" rel=\"noopener noreferrer\" target=\"_blank\">We've flagged 2 risks for SentinelOne. See which could impact your investment.</a></p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h3>Quick Assessment</h3> <ul> <li><strong>‚úÖ Price vs Analyst Target</strong>: At $13.48 versus an average analyst target of $20.71, the price sits about 35% below consensus expectations.</li> <li><strong>‚úÖ Simply Wall St Valuation</strong>: Shares are described as trading 44.4% below an estimated fair value, which flags potential upside based on that model.</li> <li><strong>‚ùå Recent Momentum</strong>: The stock has a 30 day return of about 10.8% decline, so the market has been cautious recently.</li> </ul> <p>There is only one way to know the right time to buy, sell or hold SentinelOne: head to Simply Wall St's\n<a class=\"company-report-links\" href=\"https://www.simplywall.st/stocks/us/software/nyse-s/sentinelone/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">company report for the latest analysis of SentinelOne's Fair Value</a>.</p> <h3>Key Considerations</h3> <ul> <li>üìä The new identity platform extends SentinelOne's reach into protecting both human and AI agent accounts, which could broaden its role in zero trust and automation heavy environments.</li> <li>üìä Keep an eye on customer adoption, any commentary on AI related deal wins, and whether revenue of US$955.65m starts to reflect traction from this product line.</li> <li>‚ö†Ô∏è The company is currently loss making with net income of a US$411.29m loss and is flagged as not forecast to reach profitability within 3 years, so funding and cash burn remain key watchpoints.</li> </ul> <h3>Dig Deeper</h3> <p>For the full picture including more risks and rewards, check out the\n<a class=\"company-report-links\" href=\"https://www.simplywall.st/stocks/us/software/nyse-s/sentinelone\" rel=\"noopener noreferrer\" target=\"_blank\">complete SentinelOne analysis</a>. Alternatively, you can visit the\n<a class=\"company-report-links\" href=\"https://www.simplywall.st/stock/NYSE/S\" rel=\"noopener noreferrer\" target=\"_blank\">community page for SentinelOne</a> to see how other investors believe this latest news will impact the company's narrative.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-02-28 01:10:51",
            "link": "https://simplywall.st/stocks/us/software/nyse-s/sentinelone/news/sentinelone-unveils-identity-platform-as-market-weighs-losse",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "United Therapeutics Tresmi Launch And Xenotransplant Progress Shape Valuation Story",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>United Therapeutics (NasdaqGS:UTHR) has introduced Tresmi, a new soft mist inhaler platform aimed at reducing treatment side effects, including coughing.</li> <li>The company reported record annual revenue alongside this product launch.</li> <li>United Therapeutics also reported tangible progress in its organ manufacturing program focused on xenotransplantation.</li> </ul> <p>For investors watching United Therapeutics at a share price of $503.6, these updates add fresh detail to the story behind NasdaqGS:UTHR. The stock is up 4.8% over the past week and 55.6% over the past year, with a very large 3-year gain and a 214.1% return over 5 years. In that context, the combination of a new inhaler platform, record revenue, and organ manufacturing progress provides more detail on recent share price strength.</p> <p>Looking ahead, Tresmi may influence how the company positions its inhaled therapies, particularly if reduced coughing is associated with better patient adherence. Progress in xenotransplantation research may also inform how investors view the company‚Äôs long-term pipeline and potential new revenue streams. Together, these developments may be important for how the market values future opportunities at United Therapeutics.</p> <p>Stay updated on the most important news stories for <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-uthr/united-therapeutics/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">United Therapeutics</a> by adding it to your <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a>. Alternatively, explore our <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/stock/NasdaqGS/UTHR\" rel=\"noopener noreferrer\" target=\"_blank\">Community</a> to discover new perspectives on United Therapeutics.</p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-uthr/united-therapeutics/future\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NasdaqGS:UTHR Earnings &amp; Revenue Growth as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/f0981ea6-8c55-4492-9a4c-3acc364f2deb/chart/earnings-and-revenue-growth?date=2026-02-27\" width=\"746\"/></a><figcaption>NasdaqGS:UTHR Earnings &amp; Revenue Growth as at Feb 2026</figcaption></figure> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_news_risk_alert\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-uthr/united-therapeutics\" rel=\"noopener noreferrer\" target=\"_blank\">We've flagged 0 risks for United Therapeutics. See which could impact your investment.</a></p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h3>Quick Assessment</h3> <ul> <li><strong>‚öñÔ∏è Price vs Analyst Target</strong>: At US$503.6 versus a US$565.08 consensus target, the price sits about 11% below analyst expectations, which indicates potential upside in the current analyst view.</li> <li><strong>‚úÖ Simply Wall St Valuation</strong>: Simply Wall St currently sees United Therapeutics trading about 68.1% below its estimated fair value.</li> <li><strong>‚úÖ Recent Momentum</strong>: The 30 day return of roughly 5.6% reflects positive short term momentum as the market absorbs the Tresmi launch and organ manufacturing update.</li> </ul> <p>The decision to buy, sell or hold United Therapeutics depends on your own analysis. For more detail, see Simply Wall St's\n<a class=\"company-report-links\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-uthr/united-therapeutics/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">company report for the latest assessment of United Therapeutics's fair value</a>.</p> <h3>Key Considerations</h3> <ul> <li>üìä Tresmi and progress in xenotransplantation add another layer to the story alongside record revenue and existing pulmonary hypertension therapies.</li> <li>üìä It may be useful to monitor adoption of the new inhaler, any reported impact on side effects, and updates on organ manufacturing milestones or regulatory steps.</li> <li>‚ö†Ô∏è Execution risk around commercial uptake of Tresmi and the scientific, regulatory and cost hurdles in xenotransplantation could influence how quickly these projects affect results.</li> </ul> <h3>Dig Deeper</h3> <p>For a fuller picture, including additional risks and potential rewards, see the\n<a class=\"company-report-links\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-uthr/united-therapeutics\" rel=\"noopener noreferrer\" target=\"_blank\">complete United Therapeutics analysis</a>. You can also visit the\n<a class=\"company-report-links\" href=\"https://www.simplywall.st/stock/NasdaqGS/UTHR\" rel=\"noopener noreferrer\" target=\"_blank\">community page for United Therapeutics</a> to see how other investors view the latest developments and their impact on the company's narrative.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><p>‚Ä¢ Dividend Powerhouses (3%+ Yield)<br/>‚Ä¢ Undervalued Small Caps with Insider Buying<br/>‚Ä¢ High growth Tech and AI Companies<br/><br/>Or build your own from over 50 metrics.</p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/stock-screener\" target=\"_blank\">Explore Now for Free</a></div></div>",
            "pub_date": "2026-02-28 01:01:46",
            "link": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-uthr/united-therapeutics/news/united-therapeutics-tresmi-launch-and-xenotransplant-progres",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Is Earnings Beat And New Audit Voice Altering The Investment Case For Darling Ingredients (DAR)?",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>Darling Ingredients recently reported quarterly revenues that came in well above analyst expectations, with management highlighting strong operational execution, EBITDA growth and improved gross margins despite industry headwinds.</li> <li>The company also disclosed a planned 2026 retirement of long-time lead director Gary Mize and the immediate addition of former Cargill executive Robert Aspell to the board and Audit Committee, potentially sharpening oversight around global agriculture exposure and risk management.</li> <li>Against this backdrop of earnings outperformance and fresh audit expertise from Robert Aspell, we‚Äôll assess how Darling Ingredients‚Äô investment narrative may evolve.</li> </ul><p>Invest in the nuclear renaissance through our list of <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/473644/nuclear-renaissance/global\" rel=\"noopener noreferrer\" target=\"_blank\">84 elite nuclear energy infrastructure plays</a> powering the global AI revolution.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Darling Ingredients Investment Narrative Recap</h2><p>To own Darling Ingredients, you need to believe its mix of rendering, renewable fuels and specialty ingredients can translate volatile inputs and policy swings into steadier cash generation. The latest revenue beat and margin improvement support that thesis, but do not materially change the near term focus on renewable fuel policy clarity as the key catalyst, or on weak recent profitability and high leverage as central risks.</p> <p>The most relevant development for that near term story is the board change. Adding former Cargill executive Robert Aspell, with deep global agriculture and risk experience, to the Audit Committee could sharpen oversight around feedstock exposure, capital allocation and compliance just as Darling works through margin volatility and balance sheet constraints in its Fuel and Feed segments.</p> <p>Yet against the recent earnings volatility and tight interest coverage, one area investors should be especially aware of is the risk that prolonged regulatory uncertainty could...</p> <p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/food-beverage-tobacco/nyse-dar/darling-ingredients/m6tj1w9q-us-renewable-mandates-and-specialty-ingredients-will-power-market-evolution-ybid\" rel=\"noopener noreferrer\" target=\"_blank\">Read the full narrative on Darling Ingredients (it's free!)</a></p><p>Darling Ingredients' narrative projects $6.5 billion revenue and $673.1 million earnings by 2028.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/food-beverage-tobacco/nyse-dar/darling-ingredients/m6tj1w9q-us-renewable-mandates-and-specialty-ingredients-will-power-market-evolution-ybid\" rel=\"noopener noreferrer\" target=\"_blank\">Uncover how Darling Ingredients' forecasts yield a $47.46 fair value</a>, a 10% downside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/us/food-beverage-tobacco/nyse-dar/darling-ingredients\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"DAR 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/ddd8b6e1-179a-4580-91d0-0fba71c1152c/chart/quote-price\" width=\"746\"/></a><figcaption>DAR 1-Year Stock Price Chart</figcaption></figure> <p>Some of the most optimistic analysts expect revenue near US$6.8 billion and earnings around US$891.1 million by 2028, whereas concerns about rising capex and regulatory dependence paint a much tougher picture, and this quarter‚Äôs earnings beat and governance changes could ultimately shift how you weigh those competing views.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/food-beverage-tobacco/nyse-dar/darling-ingredients\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 3 other fair value estimates on Darling Ingredients</a> - why the stock might be worth 10% less than the current price!</p><h2>The Verdict Is Yours</h2><p>Don't just follow the ticker - dig into the data and build a conviction that's truly your own.</p><ul><li>A great starting point for your Darling Ingredients research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/food-beverage-tobacco/nyse-dar/darling-ingredients\" rel=\"noopener noreferrer\" target=\"_blank\">2 key rewards and 4 important warning signs</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/food-beverage-tobacco/nyse-dar/darling-ingredients\" rel=\"noopener noreferrer\" target=\"_blank\">Our free Darling Ingredients research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Darling Ingredients' overall financial health at a glance.</li></ul><h2>Contemplating Other Strategies?</h2><p>Our daily scans reveal stocks with breakout potential. Don't miss this chance:</p><ul><li>Find <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">54 companies with promising cash flow potential yet trading below their fair value</a>.</li><li>We've uncovered the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473528/dividend-fortresses/us\" rel=\"noopener noreferrer\" target=\"_blank\">15 dividend fortresses</a> yielding 5%+ that don't just survive market storms, but thrive in them.</li><li>Capitalize on the AI infrastructure supercycle with our selection of the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473744/ai-infrastructure-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">33 best 'picks and shovels' of the AI gold rush</a> converting record-breaking demand into massive cash flow.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-02-28 01:01:46",
            "link": "https://simplywall.st/stocks/us/food-beverage-tobacco/nyse-dar/darling-ingredients/news/is-earnings-beat-and-new-audit-voice-altering-the-investment",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Assessing Lithia Motors (LAD) Valuation After Recent Share Price Pullback",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Why Lithia Motors stock is drawing attention now</h2> <p>Lithia Motors (LAD) has been on many investors‚Äô radar after recent share performance, with the stock showing a negative move over the month and past 3 months, prompting closer scrutiny of its current valuation.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/us/retail/nyse-lad/lithia-motors\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for Lithia Motors.</a></p> <p>At a share price of $281.46, Lithia Motors has seen a 1 day share price return of 0.69%, set against a weaker 30 day share price return of 13.97% and a 1 year total shareholder return of 17.7%. Together, these figures point to fading momentum after earlier gains over three years.</p> <p>If this pullback has you thinking about where else capital could work harder, it might be a good time to broaden your search with our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_founder_led\" href=\"https://simplywall.st/discover/investing-ideas/473625/top-founder-led-companies/us\" rel=\"noopener noreferrer\" target=\"_blank\">19 top founder-led companies</a>.</p> <p>With Lithia trading at $281.46, an indicated 58.71% discount to one intrinsic value estimate and a 39.81% discount to the average analyst target of $393.50, you have to ask: is this a genuine opportunity, or is the market already factoring in future growth?</p> <h2>Most Popular Narrative: 28.7% Undervalued</h2> <p>On the most followed narrative, Lithia Motors' fair value of $394.57 sits well above the current $281.46 share price, which puts a lot of focus on what is driving that gap.</p> <blockquote> <p><em>Ongoing technology investments, especially the full rollout of Pinewood.AI, are expected to materially lower SG&amp;A through automation, unified workflows, and improved productivity, driving operating leverage that should improve net margins and efficiency ratios over the next several years.</em></p> </blockquote> <p><em><a class=\"company-report-links\" data-vars-link-type=\"cta_narrative_prompt_after_quote\" href=\"https://www.simplywall.st/narratives/g0g50k5y-analysts-lift-lithia-motors-price-target-as-buybacks-and-expansions-drive-improved-margins\" rel=\"noopener noreferrer\" target=\"_blank\">Read the complete narrative.</a></em></p> <p>If you want to see what is really baked into that valuation, the core of this narrative is a specific mix of revenue growth, margin uplift, and future earnings multiples that are anything but conservative.</p> <p><strong>Result: Fair Value of $394.57 (UNDERVALUED)</strong></p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_ai_narrative\" href=\"https://www.simplywall.st/narratives/g0g50k5y-analysts-lift-lithia-motors-price-target-as-buybacks-and-expansions-drive-improved-margins\" rel=\"noopener noreferrer\" target=\"_blank\">Have a read of the narrative in full and understand what's behind the forecasts.</a></p> <p>However, you also have to keep an eye on risks such as elevated acquisition costs or weaker organic store performance, which could challenge those margin and earnings assumptions.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/us/retail/nyse-lad/lithia-motors\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this Lithia Motors narrative.</a></p> <h2>Next Steps</h2> <p>With both risks and rewards on the table, what matters most is how you weigh them for your own portfolio. Take a closer look at the full picture and let the data guide your stance through <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/us/retail/nyse-lad/lithia-motors\" rel=\"noopener noreferrer\" target=\"_blank\">5 key rewards and 1 important warning sign</a>.</p> <h2>Looking for more investment ideas?</h2> <p>If Lithia has sparked new questions about where your money works hardest, do not stop here. Let the screener surface fresh angles you might be missing.</p> <ul> <li>Target potential value opportunities by scanning companies on our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">54 high quality undervalued stocks</a> and see which ones match your return expectations and risk comfort.</li> <li>Prioritise stability by reviewing companies highlighted in the <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_low_risk\" href=\"https://simplywall.st/discover/investing-ideas/473631/low-risk-leaders/us\" rel=\"noopener noreferrer\" target=\"_blank\">80 resilient stocks with low risk scores</a>, so you can focus on businesses with lower overall risk scores.</li> <li>Hunt for lesser known prospects through our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undiscovered_gems\" href=\"https://simplywall.st/discover/investing-ideas/473622/high-quality-undiscovered-gems/us\" rel=\"noopener noreferrer\" target=\"_blank\">screener containing 24 high quality undiscovered gems</a> and spot companies that may not yet be widely followed.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><p>‚Ä¢ Dividend Powerhouses (3%+ Yield)<br/>‚Ä¢ Undervalued Small Caps with Insider Buying<br/>‚Ä¢ High growth Tech and AI Companies<br/><br/>Or build your own from over 50 metrics.</p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/stock-screener\" target=\"_blank\">Explore Now for Free</a></div></div>",
            "pub_date": "2026-02-28 01:01:45",
            "link": "https://simplywall.st/stocks/us/retail/nyse-lad/lithia-motors/news/assessing-lithia-motors-lad-valuation-after-recent-share-pri-1",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Is Iovance Biotherapeutics (IOVA) Attractive After Recent 33% Weekly Share Price Jump",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>If you are wondering whether Iovance Biotherapeutics at around US$3.79 is a bargain or a value trap, you are not alone. This article will walk through what the current price could mean for you.</li> <li>The stock has recently moved sharply, with a 33% return over the last 7 days, 27.2% over the last 30 days, and 50.4% year to date, even though the 1 year, 3 year and 5 year returns remain negative.</li> <li>These swings have come as investors react to ongoing developments around Iovance Biotherapeutics and its pipeline, which can quickly change sentiment around early stage biotech names. Understanding what is already baked into the share price matters if you are trying to work out whether recent moves reflect lasting shifts in expectations or short term trading.</li> <li>On our valuation checks the company scores <a class=\"company-report-links\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">4 out of 6</a> for being undervalued. Next we will look at how different valuation approaches line up on Iovance Biotherapeutics, and then finish with a way to put those numbers into a fuller investment story.</li> </ul> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_industry_underperformer\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics/future\" rel=\"noopener noreferrer\" target=\"_blank\">Find out why Iovance Biotherapeutics's -27.9% return over the last year is lagging behind its peers.</a></p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Approach 1: Iovance Biotherapeutics Discounted Cash Flow (DCF) Analysis</h2> <p>A Discounted Cash Flow, or DCF, model takes estimates of a company‚Äôs future cash flows and discounts them back to today to arrive at an estimate of what the business could be worth right now.</p> <p>For Iovance Biotherapeutics, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flow projections in US$. The latest twelve month free cash flow is a loss of about $343.7 million. Analysts provide forecasts out to 2030, with free cash flow projections moving from a loss of $146 million in 2026 and $13 million in 2027, to positive cash flows of $143 million in 2028, $231 million in 2029 and $313 million in 2030. Beyond the analyst horizon, Simply Wall St extrapolates further free cash flow estimates out to 2035 using its own growth assumptions.</p> <p>When all of those projected cash flows are discounted back to today, the DCF model arrives at an estimated intrinsic value of about $23.63 per share. Compared with the recent share price around $3.79, this implies the stock is about 84.0% undervalued on this measure.</p> <p><strong>Result: UNDERVALUED</strong></p> <p>Our Discounted Cash Flow (DCF) analysis suggests Iovance Biotherapeutics is undervalued by 84.0%. Track this in your <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_undervalued\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_undervalued\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a>, or discover <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">54 more high quality undervalued stocks</a>.</p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"IOVA Discounted Cash Flow as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/af2848b1-cfd3-42ac-adb3-fafd0b7d60eb/chart/dcf?date=2026-02-27\" width=\"746\"/></a><figcaption>IOVA Discounted Cash Flow as at Feb 2026</figcaption></figure> <p><a class=\"company-report-links\" data-vars-link-type=\"dcf_explainer_cta\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Iovance Biotherapeutics.</a></p> <h2>Approach 2: Iovance Biotherapeutics Price vs Sales</h2> <p>For companies that are not yet profitable, the P/S ratio is often more useful than P/E because it compares what investors are paying to the revenue being generated, rather than to earnings that are still negative.</p> <p>In general, higher expected growth and lower perceived risk can support a higher P/S ratio. Slower growth or higher risk tends to justify a lower one. That is why it helps to look at Iovance Biotherapeutics in the context of both its industry and its own fundamentals.</p> <p>Iovance Biotherapeutics currently trades on a P/S of 5.93x. This sits below the Biotechs industry average of 12.58x and also below the peer average of 6.82x provided. Simply Wall St‚Äôs Fair Ratio for the company is 4.19x, which is an estimate of the P/S multiple that might be reasonable given factors such as earnings growth, profit margins, industry, market cap and specific risks. Compared with simple peer or industry comparisons, the Fair Ratio aims to be more tailored to the company‚Äôs profile.</p> <p>Putting that together, Iovance Biotherapeutics‚Äô actual P/S of 5.93x is above the Fair Ratio of 4.19x, which points to the shares pricing in a richer multiple than this framework suggests.</p> <p><strong>Result: OVERVALUED</strong></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NasdaqGM:IOVA P/S Ratio as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/af2848b1-cfd3-42ac-adb3-fafd0b7d60eb/chart/ps-multiple-vs-industry?date=2026-02-27\" width=\"746\"/></a><figcaption>NasdaqGM:IOVA P/S Ratio as at Feb 2026</figcaption></figure> <p>P/S ratios tell one story, but what if the real opportunity lies elsewhere? <a class=\"company-report-links\" data-vars-link-type=\"cta_preferred_multiple_contextual\" href=\"https://simplywall.st/discover/investing-ideas/473625/top-founder-led-companies/us\" rel=\"noopener noreferrer\" target=\"_blank\">Start investing in legacies, not executives. Discover our 19 top founder-led companies</a>.</p> <h3>Upgrade Your Decision Making: Choose your Iovance Biotherapeutics Narrative</h3> <p>Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives, which are simply your story about Iovance Biotherapeutics tied directly to numbers like future revenue, earnings, margins and a fair value estimate.</p> <p>On Simply Wall St‚Äôs Community page, millions of investors use Narratives as an accessible tool to connect a company‚Äôs story to a financial forecast and then to a fair value. This allows you to compare that fair value with the current share price to help decide if the stock looks attractive or stretched on your assumptions.</p> <p>Because Narratives update automatically when new information such as company announcements, earnings or analyst revisions appear, you are not locked into a static view. You can quickly see how fresh data shifts the fair value output linked to your story.</p> <p>For Iovance Biotherapeutics, one investor might build a cautious Narrative anchored around a US$1.00 fair value while another might build an optimistic Narrative around US$20.00. By setting out the revenue, earnings and P/E assumptions behind each, you can decide which version feels closer to your own view or adjust the inputs to create something in between.</p> <p>For Iovance Biotherapeutics, we will make it easy for you with previews of two leading Iovance Biotherapeutics Narratives:</p> <p><a href=\"/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics/13svd0s7-amtagvi-and-new-til-will-meet-aging-global-demand?utm_medium=finance_user&amp;utm_campaign=cta_bull_narrative_link&amp;utm_source=post\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong>üêÇ Iovance Biotherapeutics Bull Case</strong></a></p> <p>Fair value in this bullish narrative: US$17.00 per share</p> <p>Implied discount to this fair value versus the recent US$3.79 share price: about 78% below the narrative fair value</p> <p>Revenue growth assumption in this narrative: 56.96% a year</p> <ul> <li>Assumes Amtagvi adoption, broader patient access, and efficiency gains support higher revenue and a turnaround from losses to profit over the next few years.</li> <li>Builds in a higher profit margin and a future P/E of 75.10x, which is well above the current US Biotechs industry P/E referenced earlier in the article.</li> <li>Anchors on a Fair Value of US$17.00, based on bullish analyst assumptions for revenue of US$1.0b and earnings of US$126.3m by 2028, discounted back at about 7.11%.</li> </ul> <p><a href=\"/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics/jv6qnzu7-rising-interest-rates-and-dilution-will-stifle-til-progress?utm_medium=finance_user&amp;utm_campaign=cta_bear_narrative_link&amp;utm_source=post\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong>üêª Iovance Biotherapeutics Bear Case</strong></a></p> <p>Fair value in this bearish narrative: US$2.00 per share</p> <p>Implied premium to this fair value versus the recent US$3.79 share price: about 89% above the narrative fair value</p> <p>Revenue growth assumption in this narrative: 43.28% a year</p> <ul> <li>Assumes slower commercialization, high costs, complex distribution, and pressure from drug pricing scrutiny and interest rates, with continued execution risk.</li> <li>Uses a lower profit margin of 3.20% and a future P/E of 50.65x, while still baking in material revenue growth from Amtagvi and the pipeline.</li> <li>Arrives at a Fair Value of US$2.00 per share, reflecting a cautious view that the market may be pricing in more growth and profitability than these assumptions support.</li> </ul> <p>Together, these Narratives frame the recent US$3.79 share price between a bullish fair value of US$17.00 and a bearish fair value of US$2.00. Your job is to decide which story, or something in between, best fits your own expectations for Iovance Biotherapeutics.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_generic_community_narrative\" href=\"https://simplywall.st/features/community-narratives\" rel=\"noopener noreferrer\" target=\"_blank\">Curious how numbers become stories that shape markets? Explore Community Narratives</a></p> <p>Do you think there's more to the story for Iovance Biotherapeutics? <a class=\"company-report-links\" data-vars-link-type=\"cta_create_narrative_community\" href=\"https://simplywall.st/stock/NasdaqGM/IOVA\" rel=\"noopener noreferrer\" target=\"_blank\">Head over to our Community to see what others are saying!</a></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NasdaqGM:IOVA 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/af2848b1-cfd3-42ac-adb3-fafd0b7d60eb/chart/quote-price?date=2026-02-27\" width=\"746\"/></a><figcaption>NasdaqGM:IOVA 1-Year Stock Price Chart</figcaption></figure> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><p>‚Ä¢ Dividend Powerhouses (3%+ Yield)<br/>‚Ä¢ Undervalued Small Caps with Insider Buying<br/>‚Ä¢ High growth Tech and AI Companies<br/><br/>Or build your own from over 50 metrics.</p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/stock-screener\" target=\"_blank\">Explore Now for Free</a></div></div>",
            "pub_date": "2026-02-28 01:01:45",
            "link": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics/news/is-iovance-biotherapeutics-iova-attractive-after-recent-33-w",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        }
    ]
}